Patent application title: Production of rAAV in Vero Cells Using Particular Adenovirus Helpers
Inventors:
Clifford J. Beall (Gahanna, OH, US)
Kelly R. Clark (Columbus, OH, US)
Philip R. Johnson, Jr. (Wynnewood, PA, US)
Assignees:
NATIONWIDE CHILDREN'S HOSPITAL, INC.
IPC8 Class: AC12N700FI
USPC Class:
4352351
Class name: Chemistry: molecular biology and microbiology virus or bacteriophage, except for viral vector or bacteriophage vector; composition thereof; preparation or purification thereof; production of viral subunits; media for propagating
Publication date: 2011-08-18
Patent application number: 20110201088
Abstract:
The present invention relates to methods and materials for recombinant
adeno-associated virus production. More particularly, in some embodiments
the invention contemplates the use of an adenovirus known as Simian
Adenovirus 13 (SAdV-13) and Vero cells for production of recombinant
adeno-associated virus (rAAV).Claims:
1. A method of producing infectious recombinant adeno-associated virus
(rAAV) comprising the steps of: a) infecting a Vero producer cell with
simian adenovirus 13 (SAdV-13) helper virus and b) culturing the cell to
produce rAAV.
2. A method of producing infectious recombinant adeno-associated virus (rAAV) comprising the steps of: a) introducing a rAAV genome into a Vero packaging cell, b) infecting the cell with simian adenovirus 13 (SAdV-13) helper virus and c) culturing the cell to produce rAAV.
3. The method of claim 2 wherein the rAAV genome is introduced by infection with a rAd/AAV hybrid.
4. A method of producing infectious recombinant adeno-associated virus (rAAV) comprising the steps of: a) introducing a rAAV genome and AAV rep/cap genes into a Vero cell, b) infecting the cell with simian adenovirus 13 (SAdV-13) helper virus and c) culturing the cell to produce rAAV.
5. The method of claim 4 wherein steps a) and b) occur concurrently.
6. The method of claim 4 wherein the Vero cell is a packaging cell.
7. A method of producing infectious recombinant adeno-associated virus (rAAV) comprising the steps of: a) infecting a Vero producer cell with a SAdV-13-like adenovirus helper virus and b) culturing the cell to produce rAAV.
8. A method of producing infectious recombinant adeno-associated virus (rAAV) comprising the steps of: a) introducing a rAAV genome into a Vero packaging cell, b) infecting the cell with a SAdV-13-like adenovirus helper virus helper virus and c) culturing the cell to produce rAAV.
9. The method of claim 8 wherein the rAAV genome is introduced by infection with a rAd/AAV hybrid.
10. A method of producing infectious recombinant adeno-associated virus (rAAV) comprising the steps of: a) introducing a rAAV genome and AAV rep/cap genes into a Vero cell, b) infecting the cell with a SAdV-13-like adenovirus helper virus and c) culturing the cell to produce rAAV.
11. The method of claim 10 wherein steps a) and b) occur concurrently.
12. The method of claim 10 wherein the Vero cell is a packaging cell.
13. The method of any of claims 1-12 further comprising the step of isolating the rAAV produced by the cell.
14. The method of claim 3 or 9 wherein the Vero cell is infected with the rAd/AAV 16-24 hours after helper virus infection.
15. In a method for producing infectious recombinant adeno-associated virus (rAAV), the improvement comprising infecting a Vero cell with SAdV-13 helper virus.
16. In a method for producing infectious recombinant adeno-associated virus (rAAV), the improvement comprising infecting a Vero cell with a SAdV-13-like adenovirus helper virus.
17. A method of producing infectious rAAV comprising culturing a Vero producer cell under conditions permissive for rAAV production, wherein the Vero producer cell comprises simian adenovirus 13 (SAdV-13) helper virus.
18. A method of producing infectious rAAV comprising culturing a Vero producer cell under conditions permissive for rAAV production, wherein the Vero producer cell comprises simian adenovirus 13-like (SAdV-13-like) helper virus.
19. The method of any of the preceding claims wherein the SAdV-13 helper virus is SAdV-13 PME-12.
Description:
FIELD OF THE INVENTION
[0002] The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, the invention contemplates the use of an adenovirus known as Simian Adenovirus 13 (SAdV-13) and Vero cells for production of infectious recombinant adeno-associated virus (rAAV).
BACKGROUND
[0003] Infectious recombinant AAV are being developed as gene transfer vehicles for an ever-widening array of human applications such as for use as vaccines and gene therapy vectors. The intense interest in rAAV has been fueled by the finding that these simple vectors can efficiently transduce a variety of post-mitotic cells when administered in vivo. Promising data from animal models has resulted in the initiation of several ongoing human clinical trials. While these advances are encouraging, obstacles remain for the general implementation of rAAV as a universal gene transfer vehicle.
[0004] Adeno-associated virus (AAV) is a replication-deficient parvovirus, the single-stranded DNA genome of which is about 4.7 kb in length including 145 nucleotide inverted terminal repeat (ITRs). The nucleotide sequence of the AAV serotype 2 (AAV2) genome is presented in Srivastava et al., J. Virol., 45: 555-564 (1983) as corrected by Ruffing et al., J. Gen. Virol., 75: 3385-3392 (1994). Cis-acting sequences directing viral DNA replication (rep), encapsidation/packaging and host cell chromosome integration are contained within the ITRs. Three AAV promoters, p5, p19, and p40 (named for their relative map locations), drive the expression of the two AAV internal open reading frames encoding rep and cap genes. The two rep promoters (p5 and p19), coupled with the differential splicing of the single AAV intron (at nucleotides 2107 and 2227), result in the production of four rep proteins (Rep 78, Rep 68, Rep 52, and Rep 40) from the rep gene. Rep 78 and Rep 68, are respectively expressed from unspliced and spliced transcripts initiating at the p5 promoter, while Rep 52 and Rep 40, are respectively expressed from unspliced and spliced transcripts initiating at the p19 promoter. Rep proteins possess multiple enzymatic properties which are ultimately responsible for replicating the viral genome. Rep 78 and 68 appear to he involved in AAV DNA replication and in regulating AAV promoters, while Rep 52 and 40 appear to be involved in formation of single-stranded AAV DNA. The cap gene is expressed from the p40 promoter and it encodes the three capsid proteins VP1, VP2, and VP3. Alternative splicing and non-consensus translational start sites are responsible for the production of the three related capsid proteins. A single consensus polyadenylation site is located at map position 95 of the AAV genome. The life cycle and genetics of AAV are reviewed in Muzyczka, Current Topics in Microbiology and Immunology, 158: 97-129 (1992).
[0005] When wild type AAV infects a human cell in culture, the viral genome can integrate into chromosome 19 resulting in latent infection of the cell. Production of infectious virus does not occur unless the cell is infected with a helper virus (for example, adenovirus or herpesvirus). In the case of adenovirus, genes E1A, E1B, E2A, E4 and VA provide helper functions. Upon infection with a helper virus, the AAV provirus is rescued and amplified, and both AAV and adenovirus are produced.
[0006] AAV possesses unique features that make it attractive for delivering DNA to cells in a clinical application, for example, as a gene therapy vector or an immunization vector. AAV infection of cells in culture is noncytopathic, and natural infection of humans and other animals is silent and asymptomatic. Moreover, AAV infects many mammalian cells allowing the possibility of targeting many different tissues in vivo. The AAV proviral genome is infectious as cloned DNA in plasmids which makes construction of recombinant genomes feasible. Furthermore, because the signals directing AAV replication, genome encapsidation and integration are contained within the ITRs of the AAV genome, some or all of the internal approximately 4.3 kb of the genome (encoding replication and structural capsid proteins, rep-cap) may be replaced with foreign DNA such as a gene cassette containing a promoter, a DNA of interest and a polyadenylation signal. The rep and cap proteins may be provided in trans. Another significant feature of AAV is that it is an extremely stable and hearty virus. It easily withstands the conditions used to inactivate adenovirus (56° to 65° C. for several hours), making cold preservation of AAV-vectors less critical. AAV may even be lyophilized. Finally, AAV-infected cells are not resistant to superinfection.
[0007] Production of rAAV requires the AAV rep78/68, rcp52/40 and capsid genes and expression of their gene products, a DNA of interest flanked by AAV ITRs, helper functions provided by an adenovirus or herpesvirus helper virus, and a cell line comprising these components that is permissive for AAV replication. Examples of helper virus functions are adenovinis genes E1a, E1b, E2A, E4 and VA RNA [Carter, Adeno-associated virus helper functions in "Handbook of Parvoviruses" Vol I (P. Tjissen, Ed.) CRC Press, Boca Raton, pp 255-282 (1989)]. Wild type AAV (wt AAV) has one of the largest burst sizes of any virus following infection of cells with AAV and adenovirus. This may be well in excess of 100,000 particles per cell [Aitken et al., Hum Gene Therapy, 12:1907-1916 (2001)], while some rAAV production systems have been reported to achieve greater than 103 particles per cell. Rep proteins are absolutely required for both wt AAV and rAAV replication and assembly of intact infectious particles, as summarized in Carter et al., AAV vectors for gene therapy, in "Gene and Cell Therapy: Therapeutic Mechanisms and Strategies", Second Edition (Ed. N. Templeton-Smith), pp 53-101, Marcel Dekker, New York (2004).
[0008] A requirement for the clinical use of recombinant AAV for DNA delivery is a highly efficient scheme for production of infectious recombinant virus that is reproducible and commercially scalable. One popular mechanism of producing rAAV is to transiently transfect cells with one or more plasmids containing adenoviral helper genes, rep and cap genes, and a recombinant AAV genome. Such transfection methods are difficult to scale up, which has lead to development of stable cell line methods.
[0009] Two types of stable cell lines have been developed. In one type (producer cells), both the rAAV genome and the rep-cap genes are stably integrated into the cell DNA, while helper functions are provided by a wild-type adenovirus. As used herein, "producer cells" are those cells that are stably transformed with a rAAV genome and AAV rep/cap genes. In the second type (packaging cells), the rep and cap genes are integrated, while the rAAV genome is provided by infection with a recombinant adenovirus or herpes virus containing the rAAV genome (termed herein a "rAd/AAV hybrid" or "rHerpes/AAV hybrid"), and the helper functions are provide by a wild type adenovirus. As used herein, "packaging cells" are those cells that are stably transformed with AAV rep/cap genes.
[0010] The most common forms of these scalable systems use HeLa cells. Other cell substrates have also been used to produce AAV. One such cell substrate is a Vero cell. See, for example, U.S. Patent Application US20040224411 published Nov. 11, 2004; Handa et al., Journal of Biological Chemistry 254(14): 6603-6610 (1979); Richardson et al., Proc Natl Acad Sci USA 77(2): 931-935 (1980); and Liu et al., Journal of Virology 80(4): 1672-1679 (2006). Vero cells are derived from African green monkey kidney cells, and were identified as a cell line substrate for viral vector production. Vero cells have been used as a cell line substrate for the production of numerous human vaccines, including poliovirus (both oral and inactivated) and rabies. The safety of the cell line is attested to by pharmacovigilance of more than 20 million doses of rabies vaccine and more than 1 billion of OPV.
[0011] Vero cells have been readily adapted for growth in bioreactors on microcarriers and provide consistently high yields of viruses such as polio and rabies viruses. This allows for vaccine purity (less contaminating cell debris), large lots of vaccine (i.e., greater vaccine availability), and more economic production of vaccine. The issues of yield and adaptability to growth in bioreactors are grounds for use of Vero cells that have been provided to the Center for Biologics Evaluation and Research (CBER) division of the FDA by most manufacturers who propose to use them for vaccine production.
[0012] There remains a need in the art for new methods for scalable high titer production of rAAV from mammalian nontransformed cancer cells.
SUMMARY OF THE INVENTION
[0013] The present invention provides methods and materials useful for producing infectious recombinant AAV (rAAV). Compared to previous methods and materials, the methods and materials of the invention allow for much higher titers of rAAV to be produced and/or allow for high titer production of rAAV in mammalian cells other than transformed cancer cells.
[0014] The present invention achieves scalable high titer rAAV production using Vero cell substrates combined with simian adenovirus 13 (SAdV-13) helper virus. A particular SAdV-13 clone provided by the invention is SAdV-13 PME-12. The sequence of the clone is set out in SEQ ID NO: 16. The invention contemplates that other helper viruses like SAdV-13 or SAdV-13-like helper plasmids may also be used in the methods of the invention. A "SAdV-13-like" helper virus or helper plasmid according to the invention may be a naturally-occurring helper virus (i.e., not made by recombinant DNA techniques), or a recombinant helper virus or recombinant helper plasmid encoding one or more helper virus functions. Techniques to make recombinant helper viruses and helper plasmids are known in the art. Helper viruses of AAV are known in the art and include, for example, viruses from the family Adenoviridae and the family Herpesviridae. In some embodiments of the invention, the "SAdV-13-like" helper virus is from the Adenoviridae family including, but not limited to, a simian or human adenovirus.
[0015] In one embodiment of the invention, an "SAdV-13-like" helper virus may be a helper virus, the use of which allows rAAV production in Vero cells at a titer about equal to, equal to, or greater than the titer obtained with SAdV-13 in the assay of Example 2.
[0016] In another embodiment of the invention, an "SAdV-I 3-like" helper virus may be a helper virus that induces AAV rep gene amplification in a Vero cell that is about equal to, equal to, or greater than the amplification obtained when SAdV-13 is used. Adenovirus-dependent rep gene amplification can be readily determined by qPCR as previously described [Liu et al., Mol Ther 2:394-403 (2000)].
[0017] In yet another embodiment of the invention, an "SAdV-13-like" helper virus may be a helper virus that upregulates the expression of AAV rep, or AAV rep and cap genes, in a Vero cell so that AAV rep gene expression is about equal to, equal to, or greater than that obtained when SAdV-13 is used. Rep gene expression can be measured, for example, with a Western blot assay using anti-rep monoclonal antibody (such as clone 226.7, American Research Products).
[0018] In still other embodiment, a "SAdV-13-like" helper virus according to the invention may be a helper virus that exhibits a delayed cytopathic effect (CPE) relative to other helper viruses. These may be identified by carrying out the assay in Example 3 in Vero cells and selecting those helper viruses that take "time to reach maximal CPE about that of SAdV-13" wherein SAdV-13 and the other helper viruses are used at MOI=10. A "time to reach maximal CPE about that of SAdV-13" is a period of greater than 1 day, 2 days, 3 days, 4 days, 5 days or more than the maximal CPE of human adenovirus 5 (M01=10) in the assay. In one embodiment, the "time to reach maximal CPE about that of SAdV-13" is a period of at least 1 day more than the maximal CPE of human adenovirus 5 (MOI-10) in the assay. Alternatively, a "time to reach maximal CPE about that of SAdV-13" may be a period that is at least about 80%, 90%, 95%, 96%, 97%, 98%, 99%, 100% or greater than the time to reach maximal CPE of SAdV-13 in the assay. Other adenovinises that are reported to have delayed cytopathic effect include human Ad-8 and -19 [Schwartz et al., Invest Ophthalmol Vis Sci. 18(9):956-63 (1979)] and mouse adenovirus 1 [Nguyen et al, Gene Therapy 6, 1291-1297 (1999)].
[0019] CPE is a change in cellular morphology that occurs following viral infection. The nature of the change varies somewhat between viruses but for adenoviruses is generally recognizable by rounding of the cells and detachment from the substrate in cell culture. This causes the cell boundary to be more refractile when observed by phase contrast microscopy. Maximal CPE can be defined as a state where a vast majority of cells (i.e. >95%) display a rounded shape.
[0020] Those of skill in the art will understand that the multiplicity of infection (M01) used in these CPE assays does not necessarily mirror what would be used in method of the invention for production of rAAV. The invention contemplates that variation in host cell, helper virus and culturing conditions may necessitate using a MOI that differs from that utilized in a CPE assay, and would not require undue experimentation by one of ordinary skill in the art to determine. The MOI to be utilized in rAAV production methods of the invention is from about 1 to about 20, or from about 1 to about 100, when a naturally-occurring adenovirus is used as the helper virus. The MOI to be utilized when recombinant adenovirus is used as the helper virus is from about 1 to about 20, about 30, about 40, about 50, or about 70.
[0021] In yet another embodiment of the invention, an "SAdV-13-like" helper virus may be a helper virus that, when used in methods of the invention, results in production of a titer of at least about: 2×104 DNAse resistant particles (DRP) per cell, 2.5×104 DRP per cell, 3×104 DRP per cell, 3.5×104 DRP per cell, 4×104 DRP per cell, 4.5×104 DRP per cell, 5×104 DRP per cell, 5.5×104 DRP per cell, 6×104 DRP per cell, 6.5×104 DRP per cell, 7×104 DRP per cell, 7.5×104 DRP per cell, 8×104 DRP per cell, 8.5×104 DRP per cell, 9×104DRP per cell, 9.5×104 DRP per cell, 1×105 DRP per cell, 1.5×10) DRP per cell, 2×105 DRP per cell, or 2.5×105 DRP per cell.
[0022] In an embodiment, the invention provides methods for increasing rAAV production in a Vero cell line of at least 2-fold in comparison to use of human adenovirus 5 (HuAdS) helper virus and Vero cells. In other embodiments, the invention provides methods of increasing rAAV production in a Vero cell line of at least 3-fold, at least 3.5-fold, at least 4-fold, at least 4.5-fold, at least 5-fold, at least 10-fold, at least 20-fold or at least 50-fold.
[0023] In an embodiment of the invention, a method of producing rAAV is provided, comprising the steps of infecting a Vero producer cell with SAdV-13 and culturing the cell. See, for example, methods based on stable HeLa cell lines described in Clark et al., Hum. Gene Ther 6:1329-1341 (1995), and Tamayose et al., Hum Gene Ther 7:507-513 (1996).
[0024] In another embodiment of the invention, a method of producing rAAV is provided comprising the steps of introducing a rAAV genome into a Vero packaging cell, infecting the cell with SAdV-13 and culturing the cell. The rAAV genome may be introduced by a rAd/AAV hybrid. Vero packaging cell lines may be generated that express rep-cap genes upon adenovirus infection. rAAV is produced by infecting the packaging cell line with a recombinant adenovirus harboring a rAAV vector genome in the adenovirus E1 region or adenovirus E3 region (rAd/AAV hybrid). The corresponding E1 or E3 helper gene products are also provided for robust Ad/AAV hybrid replication. See, for example, Liu et al., Gene Ther. 6:293-299 (1999); Inoue et al., J Virol 72:7024-7031 (1998); Gao et al., Hum Gene Ther 9:2353-2362 (1998); Conway et al., Gene Ther 6:986-993 (1999); Vincent et al., Vaccine 90: 353-359 (1990); Clark et al., Hum Gene Ther 10:1031-1039 (1999); Thrasher et al., Gene Ther 2:481-485 (1995); Fisher et al., Hum Gene Ther 7:2079-2087 (1996); and Gao et al., Mol Ther 5:644-649 (2002). Upon co-infection, the rAAV vector is excised from the adenovirus genome, replicated, and packaged into infectious virions.
[0025] In still another embodiment of the invention, a method of producing rAAV is provided comprising the steps of introducing a rAAV genome and AAV rep/cap genes into a Vero cell, infecting the cell with SAdV-13 helper virus and culturing the cell. The introduction of the rAAV genome and AAV rep/cap genes into a Vero cell may occur concurrently with the infection of the cell with helper virus. Alternatively, the Vero cell may be a packaging cell. rAAV is commonly generated in cell culture by plasmid DNA transfection of mammalian cells. The plasmid components are: an AAV vector plasmid, an AAV rep-cap expressing plasmid, and an adenovirus helper plasmid or wild-type adenovirus infection. See, for example, Vincent et al., J Virol 71:1897-1905 (1997); Ogasawara et al., Microbiol Immunol 42:177-185 (1998); Li et al., J Virol 71:5236-5243 (1997); Grimm et al., Hum Gene Ther 9:2745-2760 (1998); Ferrari et al., J Virol 70:3227-3234 (1996); Xiao et al., J Virol 72:2224-2232 (1998); Collaco et al., Gene 238:397-405 (1999); Matsushita et al., Gene Ther 5:938-945 (1998); and Salvetti et al., Hum Gene Ther 9:695-706 (1998). The methods that may be utilized to introduce rep and cap genes into a cell are well known to those of ordinary skill in the art. These may include, e.g., use of a virus that encodes rep and/or cap genes to infect a cell, or use of a plasmid that encodes rep and/or cap genes to transiently transfect a cell.
[0026] In an embodiment of the invention, a method of producing rAAV is contemplated comprising the steps of infecting a Vero producer cell with a SAdV-13-like adenovirus helper virus and culturing the cell.
[0027] In another embodiment of the invention, a method of producing rAAV is provided comprising the steps of introducing a rAAV genome into a Vero packaging cell, infecting the cell with a SAdV-13-like adenovirus helper virus and culturing the cell. The rAAV genome may be introduced by a rAd/AAV hybrid.
[0028] In yet another embodiment of the invention, a method of producing rAAV is provided comprising the steps of introducing a rAAV genome and AAV rep/cap genes into a Vero cell, infecting the cell with a SAdV-13-like helper virus and culturing the cell. The introduction of a rAAV genome and AAV rep/cap genes into a Vero cell may occur concurrently with the infection of the cell with a SAdV-13-like helper virus. Alternatively, the Vero cell may be a packaging cell.
[0029] In embodiments of the invention, the rAAV produced by the methods of he invention is isolated.
[0030] In a further embodiment of the invention, methods are provided that comprise infecting a Vero packaging cell with helper virus of the invention and then with an Ad/AAV hybrid virus encoding the rAAV genome. In some embodiments, the Vero cell may be infected with the Ad/AAV hybrid virus about 16 to 24 hours after helper virus infection.
[0031] In yet another embodiment of the invention, a method is provided for producing infectious recombinant adeno-associated virus (rAAV), the improvement comprising infecting a Vero cell with SAdV-13 helper virus.
[0032] In still another embodiment of the invention, a method is provided for producing infectious recombinant adeno-associated virus (rAAV), the improvement comprising infecting a Vero cell with a SAdV-13-like adenovirus helper virus.
[0033] In an embodiment of the invention, a method of producing infectious rAAV is provided comprising culturing a Vero producer cell under conditions permissive for rAAV production, wherein the Vero producer cell comprises simian adenovirus 13 (SAdV-13) helper virus.
[0034] In another embodiment of the invention, a method of producing infectious rAAV is provided comprising culturing a Vero producer cell under conditions permissive for rAAV production, wherein the Vero producer cell comprises simian adenovirus 13-like (SAdV-13-like) helper virus.
[0035] Methods of the invention produce rAAV titers of at least about: 2×104 DNAse resistant particles (DRP) per cell, 2.5×104 DRP per cell 3×104 DRP per cell, 3.5×104 DRP per cell, 4×104 DRP per cell, 4.5×104 DRP per cell, 5×104 DRP per cell, 5.5×104 DRP per cell, 6×104 DRP per cell, 6.5×104 DRP per cell, 7×104 DRP per cell, 7.5×104 DRP per cell, 8×104 DRP per cell, 8.5×104 DRP per cell, 9×104 DRP per cell, 9.5×104 DRP per cell, 1×10' DRP per cell, 1.5×105 DRP per cell, 2×105 DRP per cell, or 2.5×105 DRP per cell. In methods of the invention, Vero cells are cultured under conditions permissive for rAAV production.
[0036] The invention contemplates that any rAAV serotype (including, but not limited to, AAV1, AAV2, AAV5, AAV6, AAV7, AAV8, AAV9, and variants thereof), pseudotype or chimera may be produced by methods of the invention.
[0037] The invention also contemplates that any rAAV genome that can be packaged in an infectious recombinant AAV (rAAV) may be used in the methods described herein. Numerous appropriate rAAV genomes are described in the art and may be used in the invention. rAAV genomes usually comprise one or more DNAs of interest flanked by AAV ITRs, or comprise an expression cassette (one or more DNAs of interest operatively linked to a promoter and polyadenylation signal for expression) flanked by AAV ITRs. The DNAs of interest may encode a protein or an RNA, as is understood in the art. In embodiments of the invention, there are no AAV rep and cap genes between the AAV ITRs of rAAV genomes.
[0038] The present invention provides for a Vero producer cell or Vero cell producer cell substrate (as used interchangeably herein) wherein the Vero producer cell comprises an rAAV ITR flanking a polynucleotide of therapeutic interest (rAAV genome) and AAV rep and cap genes. In some embodiment both the rAAV genome and the rep-cap genes are stably integrated into the Vero cell. In some embodiments either or both the rAAV genome and the AAV rep-cap genes are introduced into the Vero cell via infection with a recombinant adenovirus or recombinant herpes virus wherein the either the rep-cap genes or rAAV genome respectively is a stably integrated into the Vero cell.
BRIEF DESCRIPTION OF THE DRAWINGS
[0039] FIG. 1 depicts production of rAAV following various helper virus infections of VeroC2 cells. Cells were infected with the indicated virus at MOI=10 and rAAV DRP was quantified by DRP using qPCR. Real time PCR with primer/probe sets detecting the CMV promoter (blue) and the eGFP coding region (red) are shown.
[0040] FIG. 2 depicts infectious rAAV titers produced by VeroC2 cells upon infection with various helper viruses. Lysates were produced as described and then used for co-infection of HeLa C12 cells with human Ad5. Lysates produced with SAdV-2, 3, 10, 11, 16 or mock-infected did not produce any detectable infectious rAAV (<100 IU/ml).
[0041] FIG. 3 depicts the BamHI restriction pattern of four fosmid clones compared to SAdV-13 infected cell Flirt DNA showing an identical banding pattern consistent with isolation of an SAdV-13 molecular clone.
[0042] FIG. 4 depicts phylogenetic trees for hexon and penton protein sequences from various simian (SAdV) and human (HuAdV) adenoviruses. Bovine adenovirus sequence (BoAdA) was used to root the tree and the position of SAdV-13 is marked with arrows.
DETAILED DESCRIPTION
[0043] The present invention is illustrated by the following examples relating to the production of increased titers of rAAV using a VeroC2 cell line and SAdV-13. Example 1 describes experiments in which VeroC2 cells are infected with simian adenoviruses. Example 2 describes the level of production of rAAV as measured by a DNAse-resistant particle (DRP) assay. Example 3 describes a CPE assay used to determine the maximal CPE of various adenovirus helper viruses. Example 4 describes the production of rAAV in Vero cells. Example 5 demonstrates the development of Vero lines that could be used to produce rAAV by an alternative, scalable method. Example 6 describes rAAV production using Vero packaging cells and the Ad/AAV hybrid system with SAdV-13 helper virus. Example 7 describes the cloning and sequencing of a particular SAdV-13 helper virus named SAdV-13 (PME12). Example 8 describes the development of a qPCR assay to quantitate SAdV-13.
Example 1
[0044] The effect of use of various simian adenovirus helper viruses on rAAV expression of a heterologous gene in Vero cells was examined.
[0045] Simian adenoviruses were obtained from the American Type Culture Collection (ATCC, Manassas, Va.) and propagated by infecting LLC-MK2 cells (ATCC) in DMEM with 2% supplemented calf serum (Cosmic Calf Serum, HyClone, Logan Utah). Cleared cell lysates were prepared by four rounds of freezing and thawing followed by centrifugation to remove particulates. Virus samples were checked for the presence of wild type AAV by a PCR assay with degenerate primers as described in Chen et al., J Virol 79: 14781-14792 (2005). Viral samples that showed the presence of contaminating wild type AAV were processed by plaque purifying virus in the presence of anti-AAV1 rabbit antiserum. The PCR assay was then repeated on the new viral stocks. Viruses were titered by the TCID5o method on LLC-MK2 cells as described in the Adeno-X expression system 1 User Manual, pages 46-47 (August 2007 version, protocol PT3414, version PR7823350), Clontech Laboratories, Inc. (Mountain View, Calif.).
[0046] A producer AAV cell line was derived from the standard Vero line distributed by ATCC (Cat #CCL-81) by methods generally described in U.S. Pat. No. 5,658,785. The producer cell line named VeroC2 has three elements stably integrated in the genomic DNA: (1) the rep and cap genes of AAV2; (2) a recombinant AAV genome with a green fluorescent protein (GFP) gene; and (3) the neomycin resistance gene. The cell line was plated at 20,000 cells per well in a 24 well plate. After one day the cells were infected with a panel of monkey adenoviruses. The adenovirus was used at a multiplicity of infection (MOI) of 10. The cells were examined 1-2 days later using a fluorescent microscope that detects GFP expression as a result of recombinant genome replication and transgene expression. Simian adenoviruses that were tested were SAdV-2, 3, 5, 8, 10, 11, 13, 16, 19 and 20.
[0047] Results showed highest GFP expression in VeroC2 cells infected with SAdV-13. Lower GFP expression was noted for VeroC2 cells infected with SAdV-5, -8, and -19. GFP expression was barely detectable for VeroC2 cells infected with SAdV-2, 3, 10, 11, 16 and 20.
Example 2
[0048] The effect of use of various simian adenovirus helper viruses on rAAV particle production in Vero cells was also examined.
[0049] The level of production of rAAV was measured by the DNAse-resistant particle (DRP) assay. Vero C2 cells were infected at an MOI of 10 with SAdV-2, -3, -5, -8, -10, -11, -0.13, -16, -19, or -20. When infected cells showed maximal cytopathic effect (CPE) (evidenced by rounding and detachment) they were harvested and subjected to 4 freeze thaw cycles to lyse the cells and release the virus. Heat treatment was used to inactivate residual Ad5 (55° C. for 30 min). The samples were then diluted 1:1,000 in 50 mM KCl, 10 mM Tris pH 8.0, 5 mM MgCl2 and 50 μl of the diluted lysate was treated with DNAse I for 30 min at 37° C. The DNAse was heat inactivated at 95° C. for 10 minutes and 10 rig of Proteinase K was added and allowed to digest the rAAV capsid for 1 hr at 50° C. and then the Proteinase K was inactivated by heating at 95° C. for 20 minutes. The net effect of the two treatments is to first remove any DNA that is not packaged into viral particles, and then to degrade the viral capsid proteins and release the encapsidated viral genomes. Viral DNA was quantified by real-time qPCR using "Taqman" chemistry in a ABI 7000 real time instrument (Applied Biosystems). Two primer/probe sets were utilized, one set that detects the CMV promoter, and a second set that detects the eGFP gene. A complete list of primer/probe sets that are used in this disclosure arc shown in Table 1. The probes were labeled with 6-FAM at the 5' end and TAMRA at the 3' end. The Ad5 E4 sequences used were taken from Sagawa et al., 2004, Mol. Therapy 10, 1043.
TABLE-US-00001 TABLE 1 Sequence Primer 1 Primer 2 Probe detected sequence sequence sequence CMV-IE TGGAAATCCC CATGGTGATGC CCGCTATCCACG promoter CGTGAGTCAA GGTTTTGG CCCATTGATG SEQ ID NO 1 SEQ ID NO 2 SEQ ID NO 3 eGFP CCACTACCTG TCCAGCAGGA TGAGCAAAGACCC AGCACCCAGTC CCATGTGATC CAACGAGAAGCG SEQ ID NO 4 SEQ ID NO 5 SEQ ID NO 6 Beta gal TGGCTGGAGT CGTGCATCTG TGAGGCCGATAC GCGATCTTC CCAGTTTGA TGTCGTCGTCCC SEQ ID NO 7 SEQ ID NO 8 SEQ ID NO 9 Ad5E4 GGAGTGGAGC ACTACGTCCG TGGCATGACACTAC CGAGACAAC GCGTTCCAT GACCAACACGATCT SEQ ID NO 10 SEQ ID NO 11 SEQ ID NO 12
[0050] By comparing the results for unknown samples with a standard curve generated with known quantities of plasmid DNA, the number of copies of a sequence in the sample were determined. The numbers were converted to the numbers of rAAV genomes produced per cell (FIG. 1).
[0051] The overall results indicated that SAdV-13 was the best helper virus tested. Importantly, using SAdV-13 as the helper levels of rAAV per cell were generated that were comparable to levels attainable with HeLa-based lines. Although vector yields depend on a number of factors, the highest producing HeLa lines for any given construct tend to produce 104-105 particles per cell.
Example 3
[0052] The CPE of various helper viruses was examined.
[0053] The time to reach maximum CPE was examined for various viruses by infecting cells at MOI 10, then examining their morphology daily by phase contrast microscopy with an inverted microscope. The time to maximal CPE was defined as the first day at which at least 95% of the cells show definite rounding.
[0054] For simian adenoviruses 1, 2, 3, 5, 7, 8, 10, 11, 16, 19, and 20 on Vero cells, the time to maximal CPE was 2-3 days. For HuAd5 on Vero cells the time to maximal CPE was 3-4 days, while for HuAd5 on HeLa cells it was 2 days. For SAdV-13 on Vero cells the time to maximal CPE was 5 days.
Example 4
[0055] Recombinant AAV was produced in Vero cells.
[0056] Vero cell lysates (from Vero cells infected with SAdV-5, -8, -13, -19 and -20) were applied to HeLa-derived C12 cells that had simultaneously been infected with Ad5. HeLa C12 cells are an "indicator" line that contains the AAV2 rep and cap genes. Upon co-infection with rAAV and Ad5, the rAAV genome is massively amplified (104-105 logs) due to the presence and activity of the rep gene. Therefore, vector genome and transgene amplification arc sensitive readouts for rAAV infection. Accordingly, serial dilutions (10-1 to 10-8) of VeroC2 cell lysates infected with various adenoviruses were generated and used to infect C12 cells also infected with Ad5 to stimulate rep dependent rAAV vector genome replication. Twenty hr. post-infection the wells were examined in the inverted fluorescent microscope. The total number of green cells were counted in wells with fewer than 50, and those numbers were used to generate an infectious rAAV titer (FIG. 2).
[0057] These data further confirm that SAdV-13 was the most effective helper to produce functional rAAV from the VeroC2 cell line.
Example 5
[0058] Vero lines were also developed that could be used to produce rAAV by an alternative, scalable method. In this system, AAV rep and cap genes are integrated into the Vero cellular DNA, but the rAAV genome is delivered by an adenovirus-AAV hybrid, where an rAAV genome is integrated into the E1 region of an adenovirus vector and packaged in the adenovirus capsid. The cells are also concurrently infected with a wild type adenovirus that provides helper functions for rAAV production and also allows for replication of the Ad/AAV hybrid by providing E1 gene products that are deleted in the Ad/AAV hybrid virus. Control experiments (not shown) had demonstrated that E1 products from SAdV-13 could allow replication by an E1 deleted HuAd5 in Vero cells.
[0059] To adapt such an Ad/AAV hybrid packaging system to Vero cells, cell lines were first selected that contained the AAV rep and cap genes. All these lines were derived from the World Health Organization (WHO) certified stock of Vero cells, which was provided by the ATCC with a release from the FDA. Two constructs were used to make the stable cell lines. Both have neomycin resistance genes for selection and the rep gene from AAV2, while one has the cap gene from AAV1 (rep2cap1neo) and the other has the cap gene from AAV2 (rep2cap2neo). The two constructs were transfected into WHO Vero cells and selected for stable integration with 600 μg/ml G418. A total of 387 rep2cap1 lines and 338 rep2cap2 lines were selected. Previous experience with rAAV producer cell lines indicated that robust rep gene amplification was key to high-titer cell line. Since this is amenable to high throughput screening, an initial screen based on this property was performed. Cells were infected with SAdV-13, then after 5 days, they were lysed by the addition of 1/10th volume of 4 M NaOH, 50 mM EDTA, and 10 μg/ml herring sperm DNA. The denatured cell lysate was transferred to a positively charged nylon membrane by using a "dot blot" filtration device. The level of rep DNA amplification was determined by using a rep radiolabeled hybridization probe. The cell lines corresponding to the most highly radioactive spots were selected for further analysis. There were ten rep2cap1 and 8 rep2cap2 lines that were subjected to further characterization. These were co-infected with SAdV-13 and an Ad/AAV hybrid virus to determine rAAV vector yields using this second production platform.
[0060] Five rep2cap1 packaging cell lines and five rep2cap2 cell lines were co-infected with SAdV-13 and an Ad/AAV hybrid virus (Ad/AAV β-gal) that contained a rAAV genome harboring the β-galactosidase gene integrated into the E1 region of human Ad5. The test packaging cell lines were infected with SAdV-13 at a MOI of 1 and 20 hr later infected with Ad/AAV β-gal at a MOI of 3. After 5 days, cells were lysed by 4 rounds of rapid freezing and thawing and clarified lysates generated by centrifugation and heat treatment to inactivate residual adenovirus. A DRP assay was performed using a primer/probe combination that is specific to the β-galactosidase transgene (Table 1). The productivity for the highest producing cell lines identified in this experiment. rAAV production by Vero rep2cap 1 and rep2cap2 cell lines co-infected with SAdV-β and Ad/AAV β-gal hybrid virus are shown in Table 2.
TABLE-US-00002 TABLE 2 Cell line AAV Capsid gene source rAAV DRP/cell R2C1.SF.1B1 Serotype 1 1706 R2C2.CA.1D3 Serotype 2 2316 R2C2.SF.1B1 Serotype 2 2286
[0061] An additional control experiment was done to show that there was no residual adenovirus present that could be making β-gal sequences DNAse resistant. Recombinant adenovirus containing the β-gal transgene should have been denatured by the 56° C. heating step, and to confirm this the DRP assay was repeated but with a human Ad5 E4 primer probe set. The numbers of copies of adenovirus present by using this qPCR primer/probe set were at least 10-fold lower than the β-gal copies present in the lysates, indicating that the vast majority of the DRP values were being contributed by rAAV/β-gal particles.
[0062] This initial experiment provided proof of concept that the Ad/AAV hybrid packaging type cell line could be adapted to Vero cells. The approach has been further optimized by selecting a somewhat more productive line (R2C1.CA.8C4) for production of rAAV1. Three other simian adenoviruses were additionally tested that had shown some activity with Vero C2 cells (SAdV-5, 8 and 19) in Example 1. These helper viruses had sub-detectable levels of rAAV production in this rAd/AAV hybrid system. A key aspect of this packaging system as opposed to the producer cells is that one needs only a single cell line to produce multiple different rAAV vectors of the same serotype. This could increase efficiency and reduce cost since it would not be necessary to qualify a new cell line for each rAAV vector produced.
Example 6
[0063] An additional rAd/AAV hybrid virus encoding a heterologous protein smaller than β-galactosidase and more similar in size to proteins used for therapeutic purposes was used to optimize production parameters. The rAd/AAV hybrid virus contained the enhanced green fluorescent protein (eGFP) transgene. This gene was contemplated to package more efficiently and yield greater levels of rAAV.
[0064] Two Vero derived AAV packaging cell lines were isolated following plasmid DNA transfection. The R2C1.CA.8C3 line contains the rep gene from AAV2 and the cap gene from AAV1, while the R2C2.CA.1D3 line contains both rep and cap from AAV2. To evaluate the packaging ability of Vero-derived cells with the eGFP containing rAd/AAV hybrid, the cell lines were co-infected with the rAd/AAV hybrid virus and SAdV-13 at variable timing. The rAd/AAV hybrid virus was used at 100 vector genomes per cell, while SAdV-13 was used at 1 TCID50 per cell.
[0065] Timing of infection was varied to look at the effects on rAAV yield. Infection with the rAd/AAV hybrid virus occurred at the following times relative to the SAdV-13: 4 hours before, at the same time, or 4-24 hours after at 4 hour intervals. To determine yield, cells were harvested at maximal cytopathic effect (5 days for SAdV-13), lysed by 4 freeze thaw cycles and the lysates were then diluted 1:2000. They were then treated sequentially with DNAse and Proteinase K, and assayed by real time PCR. rAAV present in the clarified cell lysate was achieved by qPCR to measure DNAse resistant vector genomes as described previously. The levels for SAdV-13 arc shown in Tables 3 and 4.
[0066] Table 3 depicts AAV1 GFP production while Table 4 depicts AAV2 eGFP production.
TABLE-US-00003 TABLE 3 AAV1 eGFP Production Timing of Ad hybrid SAdV-13 addition (hours) DRP/Cell -4 3555 0 9216 +4 7966 +8 12427 +12 11634 +16 16272 +20 7262 +24 8522
TABLE-US-00004 TABLE 4 AAV2 eGFP Production Timing of Ad hybrid SAdV-13 addition (hours) DRP/Cell -4 86561 0 73977 +4 58256 +8 83783 +12 62963 +16 60230 +20 149504 +24 98333
[0067] The data indicates that high levels of rAAV productivity are possible with this system. Up to 150,000 DNAse resistant particles per cell were documented for the rAAV2.eGFP vector. Optimal production conditions for infection varied between cell lines, with the most effective timing being rAd/AAV hybrid virus infection 16-24 hours after SAdV-13 virus infection.
Example 7
[0068] A SadV-13 was molecularly cloned and sequenced as follows.
[0069] Low molecular weight DNA was isolated from SAdV-13 infected Vero cells by a modified Hirt DNA extraction procedure [Hirt et al., Journal of Molecular Biology, 26(2): 365-369 (1967)], and then the terminal protein was removed by treatment with Klenow fragment in the presence of three of the four dNTPs followed by S1 nuclease [Berkner et al., Nucleic Acids Res 11(17): 6003-20 (1983)]. The SAdV-13 virus genomes were then cloned into a fosmid vector (Epicentre Copy Control System) and resulting clones analyzed by digestion with BamH1 restriction enzyme for an identical restriction pattern as that observed for the bulk Hirt DNA. Four clones were identified with the expected pattern (FIG. 3). Clone #3 (SAdV13-PME12) was subsequently selected for high-throughput 454 deep sequencing.
[0070] Several clones were selected and the terminal sequences determined. Sequence of the inverted terminal repeats (ITRs) for six independent clones was obtained and shared significant homology to other published adenovirus ITR sequences. Two kinds of heterogeneity in the clones' ITR sequence was observed that were otherwise identical except for orientation. The first was that there were variable numbers of nucleotides (4-18) missing from the terminal repeat ends. Secondly, in some cases short duplications of 100-400 bp of sequence was appended to intact ITRs.
[0071] Clone SAdV13-PME12 was selected for complete sequencing and possessed a 4 bp deletion at the 5' end and a 12 bp deletion at the 3' end. A portion of the resulting sequence matched exactly the previously reported VA RNA gene sequence [Kidd et al., Virology 207(1): 32-45 (1995)] supporting that this sequence is SAdV-13. Translation of the virus sequence resulted in the clear delineation of identity between this novel isolate and previously published adenoviral genomes. SAdV-13 is clearly related to other primate adenoviruses without being notably similar to any other previously published adenovirus genomes. Phylogenetic analysis of the deduced amino acid sequences of the hexon and penton proteins is shown in FIG. 4 and the complete virus genome sequence provided as SEQ ID NO: 16. This sequence, along with the putative protein sequences expressed therefrom, are depicted in Table 5 below.
TABLE-US-00005 TABLE 5 SEQ ID NO: Description 16 SAdV-13 Viral Genome 17 E4 orf 2 18 E4 orf 3 19 E4 orf 4 20 E4 34K 21 Fiber 22 E3 14.7 (15.3) 23 U exon 24 E3 RID-beta 25 E3 RID-alpha 26 E3 CR1 beta1 27 E3 CR1-alpha1 28 E3 12.5K 29 pVIII 30 33K? 31 22K 32 100K 33 DBP 34 Protease 35 Hexon 36 pVI 27 V 38 pX? 39 pVII 40 III (penton base) 41 pTP 42 po1 43 pIIIa 44 52K 45 IVa2 C-terminus 46 IX 47 E1B 55K 48 E1B 19K 49 E1A 50 E4 orf 1
Example 8
[0072] The DNA sequence of the SAdV-13 (PME-12) clone enabled the development of a quantitative real-time PCR assay to detect SAdV-13 genomes. This assay is useful for the rapid, sensitive and precise measurement of the SAdV-13 and permits rapid optimization of virus infection conditions for increased rAAV production in this production platform.
[0073] Specifically, samples are quantitated by dilution of the sample 100 to 10.000-fold in 50 mM KCl, 10 mM Tris pH 8.0, and 5 mM MgCl2. Samples are then digested in a 50 μl volume with 175 U of DNAse I at 37° C. for 30 minutes to remove non-encapsidated viral DNA. After heating at 95° C. for 10 minutes to inactivate DNAse I, the sample is treated with 200 μg/ml proteinase K at 50° C. for 1 hour to degrade the viral capsid and other cellular proteins. After treatment at 95° C. for 30 min to inactivate Proteinase K, the viral genomes are quantitated by real time PCR with a Taqman® primer probe set as follows:
TABLE-US-00006 Forward primer: (SEQ ID NO: 13) 5'-CTTGAAGCCACGCAAGTTTA-3' Reverse primer: (SEQ ID NO: 14) 5'-TGCAAATAATCCAGCAAAGC-3' Probe: (SEQ ID NO: 15) 6-FAM-CATGTTTGCTCATCGCCCGG-TAMRA
[0074] Quantitation is carried out by comparison with a plasmid standard curve.
[0075] While the present invention has been described in terms of various embodiments and examples, it is understood that variations and improvements will occur to those skilled in the art. Therefore, only such limitations as appear in the claims should be placed on the invention.
Sequence CWU
1
50120DNAArtificial SequenceSynthetic primer 1tggaaatccc cgtgagtcaa
20219DNAArtificial
SequenceSynthetic primer 2catggtgatg cggttttgg
19322DNAArtificial sequenceSynthetic probe
3ccgctatcca cgcccattga tg
22421DNAArtificial sequenceSynthetic primer 4ccactacctg agcacccagt c
21520DNAArtificial
sequenceSynthetic primer 5tccagcagga ccatgtgatc
20625DNAArtificial sequenceSynthetic probe
6tgagcaaaga ccccaacgag aagcg
25719DNAArtificial sequenceSynthetic primer 7tggctggagt gcgatcttc
19819DNAArtificial
sequenceSynthetic primer 8cgtgcatctg ccagtttga
19924DNAArtificial sequenceSynthetic probe
9tgaggccgat actgtcgtcg tccc
241019DNAArtificial sequenceSynthetic primer 10ggagtggagc cgagacaac
191119DNAArtificial
sequenceSynthetic primer 11actacgtccg gcgttccat
191228DNAArtificial sequenceSynthetic probe
12tggcatgaca ctacgaccaa cacgatct
281320DNAArtificial SequenceSynthetic primer 13cttgaagcca cgcaagttta
201420DNAArtificial
SequenceSynthetic primer 14tgcaaataat ccagcaaagc
201520DNAArtificial SequenceSynthetic probe
15catgtttgct catcgcccgg
201632938DNAArtificial SequenceSynthetic polynucleotide 16catcatcaat
aatatacctt acaatgtaaa cagaagttaa tatgcaaatg agatgggcgt 60gtccacaact
gtgattggcc gtgacgtcaa tgggcgggcc ggtgggcggt tcgggcgggg 120cgcgtcgtgg
gaaaattacg caattattag tcattaggga tgggctgacc gcacgtgcgt 180catatgcgga
agtgcggaat ttttaactgt ttgcatgtta aatttactgt gtattgggca 240aattttgaac
gcggaagtgt ttattaaaaa aattaccggg tgacgaatgg gtggaatatt 300taccgagggc
cggggagact ttgacctatt acgtgtggta tcggggcgta ttttttttgg 360tcacgtttcc
gcgaagggtc aaaagtcccg ttttattgct ctcagtcagg tgattgtcag 420ggtatttaaa
ccggagcaga acgtcaagag gccactcttg agtgccagcg agaagagttt 480tctcctcggg
ctcttcagtt gacttgaaga agataagaaa aaatgagaac tccgcttgtg 540gagggagata
ttcccgttcg gttcgcggcg gagctgttgg ctgctttggc agaagaggta 600tttgccgatg
tggaacctcc acgggcgttt gaagatgtgt ctctgcatga tttatttgat 660ttagatgtgg
aagatagaga agatcccagt caagatgcgg tagatatgct gtttccagag 720tctctgttgc
ttgctgcgga ggagggtata gatatacctc gagacactcc acctcctttg 780gagcctccga
tggtgttaag tccactcagt cagcagcagc aggatatgcc tgatttaact 840gtgggcgatg
tgaatttact gtgttctgaa agtagcttct ccagtttgga ggaaaatgag 900ctggagaggt
gtatggcaga actggccgct agcggtgtgg caagcgtacg ggagcaggaa 960agggaagaaa
tgtcaggtac gccgtttaat ttggactatc cagaaatgcc tggctatgga 1020tgcaagtcct
gtcagtacca tcgtgagcag actggggagg ctgatatttt atgttctttg 1080tgttacctga
gacgtaatgg cgtgtttgtt tacagtaagt tgtggaccac ctggtggtgg 1140ggagggaaca
tgtgtgtgtg tggttagatt ttaatgtttt ttttaatttt aaggtcctgt 1200gtcagaggcg
gaagtagatg agcctgatac aactactgat gatcaggggc gtgcgcagtc 1260tccacccaag
ctgacccagg atgcacctgt taatgttatt agacctcgtc ctattaggcc 1320atcgtcacgt
cgcaggaatg ctgtagacag cttggaatcg ctgctggaag atgatgactg 1380tgaacctttg
gacttgacct ttaaacgtgc cagatattag gcgttactgt ttgtgtaatt 1440aaacgtgcca
ggcgttgctg tatttatgtt ctgtgagtca tgtgtaaata aagattaagt 1500actgtgtaaa
tagttattgg gtcattgttt gaatagaaga gtgggaggga ttaagtgttt 1560gttataagag
caatgaagag gcctgtggct gcagaagtcc aaatggagct tgacaggctg 1620ttagagaatt
ataacagctt aagaagggtt ttagaagagg cgtctgaaga tacttcagtt 1680tggtggcgca
agttgtttgg gtgtagagtt agtcagttag tagttcaggc taaagttgaa 1740tataaggaag
aatttgagaa acttttttca gaggtgcctg gacttgtgga ctctctaaat 1800ttttgccatc
acgctttttt ttacgagaag gttatttgcg gcttggattt ttgcactccc 1860ggacgcacta
ttgcagcttt ggctttttgc gcttttattt tagataagtg gaataaggag 1920actcatctca
gtaaaggata tactttagat tacattagtt tgcagctatg gaaggcttac 1980atgaggaagg
ggaagatcta caccttctcg caggggccgc ggtcgctgcc gcagcgggtg 2040cggaggcggt
tggggttcaa gacagaggac caaacgcgct tgctggaggc cgaggaggag 2100cccagggcgg
ggacggatcc cccgagcgag acttgagtga cgaccaggag gtgcccgctg 2160cggtggggcc
tattccggac ccttttcctg agctgcgtag acatttgttg cgttctcctg 2220gtcgggggct
ggaagaagat cctggggaag gggggagtgg agaacaaaga gggattaaga 2280gacctagaga
gggacggaag gtggaaggca taatgagcga gttgacttta agtttgatga 2340ctagaaagag
gacagaaaac aagtggctca gtgagatatg ggatgagttt agaactggtg 2400atatgtatct
tcagacaaag tacacttttg agcaggtttt taccaagtgg ttaaatccag 2460aagatgattg
ggaagacgct ttaacgcgtt atggaaaggt ggctttaagg cccgatacaa 2520agtatcgttt
gactaaaaaa gtggaactca gaagctgtgc ttatgttatt ggaaacgggg 2580ctcaggtaga
agtggacatg caggaacggg tggcgtttgc ctgtaacatg gtcaatatgg 2640gtccggggat
agtggggatg ggtgggatta tttttcacaa tgtaagattt tatggagaca 2700attttaacgg
gatggttata atggcaaaca ctacggtgct tttgcatgga tgctactttt 2760ttgggtttaa
taacacggtt ttggaagtgt ggggtcatag caaggttagg gggtgtactt 2820tttacggatg
ttggaaggcc attgcttcta gacctaagag tgaaatttct gtaaaaaagt 2880gtttgtttga
aagatgtaca ttgggagtct gtgtggaagg gaaaggacgg atatttaata 2940atgtggcttc
ggaaaatgga tgttttgctt tgattaaggg ctttgccgct ttaaagtata 3000atatgatttg
tggccagtct cctaccgaga gaacatacca gatgttaaca tgtgcagatg 3060gaaatgtaca
tttgttaaag acggtgcata ttactggtca tgcaaaaaag ccctggcctt 3120tgtttgagca
taatgtgctt actagatgtt ctgtgcattt gggtcctcgg cgggggattt 3180ttattccaca
ccagtgtaat tttagccata caaatgtgtt ggtggaaacc gaagctgtaa 3240cccgtttttc
gttaacgggt gtgtttgata tgtctgtggt gatttataaa atcctgcggt 3300atgaggaaac
aaaagctaga tgtcgctgct gtgagtgcgg tggaaagcat ttgagaaatc 3360agcctgtgat
tgtggatgtc actgaagaag tgaggatgga tcatatgcag cattcttgcg 3420cccgggctga
ttattctacg gatgaagata ccgaataggt gagtatgaga ggggcggggt 3480tataaaagtc
tataaaagct ggtctaaaac aaaaaaattt ttatgttgca gcgctcatca 3540tgagtgggac
aacgtctggt tccgtcactt tcgatggagg agtgtacagt ccttttctga 3600catcgcgcct
tccgaactgg gctggagtgc gtcagaatgt tatgggatca actgtggagg 3660ggcatcctgt
attaccttct aattctgctt ctatgcgcta cgctacaatc ggatcttctt 3720cgctggacac
cgccgccgcc gcagcagctt cagccgcagc gtccgccact cgtgttctgg 3780cagctgattt
tggcttgtat ggcaatttca ctcccgctgc cgtaccccgc actgttcacg 3840atgacagctt
actgactgtg ctgactaagt tggacaattt aacgcagcag ctgggggagc 3900tttctcgtcg
ggtagctgag ttggccgaag aaagaacggt ttaaaaaata aaatgcaata 3960aattcaagtt
taaaaaattt tttattgtct gttttttttg tgataagctc gggaccacct 4020ttctctgtca
ttcaaaactt tgtgaatttt ttccattaca cgatagagat gggtttgaat 4080gttaaggtac
atgggcatga gtccatcttt ggggtggaga taagaccact gaagggcttc 4140gtgttcgggg
gtggtattat atattatcca gtcatatgag ttacgttggg cgtgatgttg 4200aaagatgtct
ttcaacaaga gggtgatagc tactggaagg cctttagtgt aagtgttaat 4260aaaccgatta
agttgggagg ggtgcatgcg gggggacatg atatgcagtt tagactggat 4320ttttaggttg
gatatgtttc cgcctaggtc tctacggggg ttcatgttgt gcagtactac 4380caggacggta
tatcccgtac atttgggaaa cttatcgtga agcttagaag ggaaagcgtg 4440gaaaaatttg
gagatccctt tatgaccgcc taggttttcc atgcattcat ccataataat 4500agctatgggg
ccctggacgg cggctcgagc gaagacgttt ctgggatccg ttacatcata 4560attatagtct
tgggtgagct cgtcatagga cattttatga aaccgaggtt ttaaggtacc 4620tgattgggga
actagggtgc cttctggccc ggctctgaag tttccttcgc agatttgcat 4680ctcccaggct
ttaatttctg cagggggaat catatctacc tgtggagcaa taaaaaaaac 4740tgtttcgggg
gctggagaaa ttagctgggt ggacagcagg tttcgcagca attgggattt 4800gccgctgccg
gtggggccgt agattacggc aataaccggc tgtaagtggt agtttaggga 4860ggtacagctt
ccatcgtctg caagaagggg agcaacctcg ttcatcatgt cctgaacatg 4920caaattttcc
tgcactaatt ctcgcaacaa acgtggtcct ccgagcgaaa gcagttcctg 4980aagggatgca
aattttttta aaggttttag accttccgcc aaaggcatat tttgcaaaga 5040ttgacataac
agttgtaagc ggtcccagag ttctgtgacg tgttctacgg catctcgatc 5100cagtagattt
cctggtttct tgggttgggt tggctgttgc tgtaaggaac cagccggtgg 5160gcgtccagag
gtgtcagcgt catgtccttc caggggcgga gggttctcgt gagtgtggtc 5220tccgttacgg
tgaaagggtg tgctccgggt tgggcgcttg ctagggtgcg cttcaaactc 5280atccgactcg
tggagaactg ttcgtttcct ccctggtagt cggcaaggta acatttcact 5340aaaaggtcgt
agctgaggga ctctgccgcg tgacccttgg ctcgaagttt tcctttggag 5400acgtgtccgc
agcggggaca gtacagacat tgcaaggcgt aaagttttgg ggctagaaaa 5460actgattcgg
gcgcataggc gtccgcgccg cacttttcac acaccgtttc gcattcaacc 5520agccaagtta
gttcggggtg ggaggggtca aaaaccagcc tccctccgtt ttttttgatt 5580cttttcctac
cttttgtttc catgagttgg tgtcccaaat ctgtcacgaa aaggctgtca 5640gtgtctccgt
acacggattt caggggtcgc tcagagagag gtgtgccgcg atcctcttcg 5700tagagaaact
ctgaccattc tgagacgaaa gcacgagtcc aagccaacac aaaggatgcg 5760atctgagaag
gatagcggtc gttgtcaatt agggggtcgg tattttccaa cgtgtgaaga 5820cacaggtctg
tttcttccgc atccaaaaaa atgattggtt tgtaagtgta tgtcacgtgg 5880ctttgggggt
cctgcggtgg gctataaaag gggggattcc accgttcctc gtcactttct 5940tccggttcgc
tgtccacgag cgctagctct ttgggtgagt aaacacgttg gaaagaaggc 6000aacacttccg
cgctgaggtt gtcagtttct ataaaagagg aggatttgat attaatgtgc 6060ccacttgcta
tcccttttaa ggttttatcg tcaagttggt cagaaaaaac agttttttta 6120ttgtccagtt
tggtagcgaa ggagccgtat agggcgttgg aaagcagttt tgcaatggat 6180ctcagcgttt
gatttttgtc tttgtcggct ttttctttgg cggcgatgtt gagctgcaca 6240tattccctgg
ctacgcattt ccactgagga aaaacggtag tgcgttcatc tggaatcaac 6300cgcactttcc
agcctcggtt gtgcaaggtg accatgtcga tactggtagc cacttcccct 6360cgcaaacgtt
catttgtcca gcagaggcgc cccccctttc gtgagcaaaa agggggcagg 6420atgtctagca
agttttcgtc gggggggtcc gcgtctattg taaaaatgcc gggcaaaagc 6480aagcggtcaa
agtaggatat tttggaagag ctgtttagag cgtcctgcca gtttttggcc 6540gctagggctc
tttcgaacgg gttaagggga ggaccccaag gcatgggatg agtaagagca 6600gatgcgtaca
ttccacagat gtcatacaca tacaggggtt cggtgagtac tccgagatag 6660gtgggatagc
atcttcctcc ccggatgctg cttcgcacgt aatcgtacag ttcgtgggag 6720ggagcaagga
agttaggccc caagtttgtt ttctgtggtc gctgggcggt gtagagaatt 6780tggcgaaata
ttgcgtgaga attagaagag atggtgggac gttggaagac attgaagcag 6840ctgttgctgt
aaccaacggt ttcgcggatg aactgtgcgt aggaagaaaa aagtttgtca 6900acaagcgcgg
ctgtgacgat gacgtccagc gcgcaatatt ctaaggtttc ttcgatgagg 6960ttgtaatgcg
gtttgttttt tgttttccac agttcgcggt tgaggaggta ctcggcttcg 7020tctttccagt
aatttcggag cggaaacccg tcagcggttg cttggtaaga acccagcatg 7080taaaactcat
tgactgctct gtagggacag catccttttt ccactggaag ggcgtacgct 7140tgagctgcct
ttcttaaaga tgtgtgagtt aattgaaagg tgtctctaac catgactttc 7200aaaaattggt
ttttaaaatc tgagtcgtca cagtttcctt gttcccacag cgtaaaatct 7260tttcgttgtt
tgtattttgg gttgggcaga gataaggtaa cgtcgttaaa aaggattttt 7320cctgcccgag
ggataaaatt tcgagagatt ttgaatggag ccggcacgtc ggtgcggttg 7380tcaatgactt
gcgcggccaa tactatttcg tcaaaaccat tgatgttgtg accgacgata 7440tacaactcta
aaaactgggg ggagcctcta agttccgggg ccgcgaccag ttggtcatat 7500gtaagttcct
tggggtcaca aaggcctaag gtttgttgac accagaaggt tagatgaggg 7560ttttcgtctg
cgaaagtgtt ccacatgtgg tcacagagaa ccgattgcag tttgtctctg 7620aagcagcgga
actgttttcc gataaccatt ttctctgggg taattaagta aaaggtagtg 7680gggtctgcgt
gccacctgtt ccactgtagc tcgacggcca aattgactgc tgttttaacc 7740agctgggctt
ggcctgtgaa tttcattacc aacatgaaag gaaccagttg cttaccaaag 7800gaacccatcc
aggtgtaggt ttctacatcg taggtgacga acagtctttg aactgccgga 7860tgcgagccaa
tgggaaaaaa ctgaatttga cgccaccatt gtgaagattg aacggctacg 7920tgatggaagt
agaagtccct tcgacgcgcg gtgcactggt gttgatgctt gtaaaatcgg 7980gcacagtatt
cgcatctctg catgggtgtt acgtcttgaa tgagataggc tttgcgtccg 8040cgtatcaaga
aacggagagg aaaggggagt ggcacgcggg atgggctgtt gggctggggc 8100tgtttgcttt
cgtctgttgt gctttgattt tggccgtcgg ttgggaggac ggccaccttg 8160acagcgcccc
gggaaatgca agtccaaatt tcggcgaagg aaggcctcag acgagcaacg 8220agtcgttgga
cgtcgttcgt tccgcaagtg tccggcagtg tgcagaggtc agctggaaat 8280cggagtaaat
gaatttcaaa gaggcgttgt agggcgggaa gcaggtgaag gtggtatttg 8340agttctacag
gactgtggtc tcgcgtgtca atagcgtgta tcaagccgtg agcgcgagaa 8400gcaaccacgg
ttccccgtaa actttttttc agtgtcggcg acggggtcgg gcgccggggg 8460gcaggggagg
ctcggcgccg gcgggcagta ctgggagatc tacgtcggcg tgagactctg 8520gcaacggtag
gtgctgggac ctcagccggc tggcatgagc caccactcgg cgattcatgt 8580tctgtatgcg
ttgacgctgt gtaaacacca ctggtccggt tactttgaac ctgaaagaga 8640gttcgacaga
gtcaatgtct gcatcattga tggcggcctg gcgaagaatt tcgtgaacat 8700cgccggagtt
gtcctggaaa gcaatttcgg tcataagttg atcaatttct tcctcttgga 8760gctcgccccg
tcctgctcgt tctaccgtcg cagccaagtc gttagaaatg cgtcctatga 8820gctgcgaaaa
agcgccgaga ccgttttcgt tccacacgcg gctgtagact acggccccgt 8880cgtcgtcgcg
ggcccgcatg actacctgcg ccagattgag ttcgacgtgt cgactgaaaa 8940ccggatagtt
cctcagacgt tgaaaaagat agttaagggt ggtggcaatg tgctcggtaa 9000caaagaaata
catgatccat ctgcgtaagg tggactcgtt aatgtcgccc acggcttcca 9060ggcgctccat
ggcttcgtaa aagtcaatgg caaaattgaa gaactgggag tttcgagcag 9120atactgtgag
ttcttcttcc aagaggcgaa taaggtcggc cacggtggct ctcacttctt 9180cctcaaacgt
acgcggtggc acctcttctt cttcctcggc ttccattacc ggagcctcaa 9240cttccacagg
aactcgtctt cgacgtctgc gaatgggcag acgatctaca aatctctcta 9300tcatttcgcc
tctgcgtcga cgcattgttt ccgtcaccgc gcggccatcc tctcgcgggc 9360gcagctcgaa
tacgcctcct cgtaggccgc ttccttgaag cagattagct tgtctggggg 9420tatttggcaa
cgatatggcg ctgacaatac attttattaa tgtctgcaca gataacccgc 9480gcagagttct
aagcatcgtt agatccacgg gatcagcaaa gcgttgcaga aaggcgtcga 9540tccagtcaca
gtcgcaaggt aagctaagaa ccgcttcggg gggcagttcc gggcttacgg 9600cgctgctaat
gatgaaatta aaaaaggcgg actttaaacg gcgaatggtg gagaggagca 9660caacgtcttt
gggtccagct tgctgaatgc gcaaacggtc ggccatgccc caagcttctc 9720cctggcaccg
tctgagatcc ttgtagtaat cttgcatgag agtttcaacc gacacctctc 9780ggtcgtccat
tcgggtggcc ccgaatcccc tgaagggttc cagtaaggca agatcggcta 9840ccacacgttc
cataagaatg gcttgttgta tttgcgtgag ggtgttttga aagtcgtcca 9900ggtcaacaaa
gcggtgatag gctccggtgt tgatggtgta agtgcagttg gccatgactg 9960accagttgac
ggtttggtga cccggctgca gggtttcccg atattttaga cgggaatagg 10020cacgcgtttc
aaacacgtag tcgttgcacg tcctaaccag gtactggtaa cccacaagaa 10080gatgaggagg
gggcagacga aagagcggcc atccccgggt ggcaggggcg ttgggcgaca 10140ggtcttctaa
cataagacga tggtatccgt agaggtatcg cgacatccaa gatatacccg 10200ctacggtggt
agctgccctc gtaaactcct gcaccctatt ccaaatgttg cgtagcggta 10260aaaagaagtc
tacggtagga acgctttgtc ccgtaagccg ggcgcagtct tgcacgctct 10320ggagtggaag
aagagaaaaa acagtacgcg taaacggctc ttctccgtgg tctagtggaa 10380aatttgcaat
ggtatgttgg cggagctcac gggttcgaaa cccgccggct ctgccagcat 10440cggggtgatt
ggtcgtcacg tctcgaacct agccggcgaa ccctagatac ggaggagagt 10500cttttgtttt
cagatgcatc cggtgttacg acaaatgcga ccctcaaaca gcggtcccgc 10560gaccaccgct
gcgggagcag tgtgtcaggc cggcgcagga aatccgttgg aggaagtgct 10620ggacatagaa
gagggcgagg gcttggcgag actgggcgcg cactcgcctg agaggcaccc 10680tcgtgttcag
ctgaaaaagg attccagtga agcttatatt ccaccccgta acttatttag 10740agaacgaagc
ggggaggagg cggaagaaat gagggactcg cggtttagag cgggtagaga 10800gttaaaaaaa
gggttggaca gggagcgcct tttgcgaccg gaggattttg aagcccgaga 10860cagaacgggc
gtcagcgctg ccagggcaca cgtggctgcg gccgacttag tgacggctta 10920cgaacaaacc
gtgaaagaag aaatgaactt tcaaaaaagc tttaataacc acgtgcgaac 10980tttgatagca
agggaggagg tggcaatagg actaatgcat ctttgggatt ttttggaggc 11040gtatgttcag
aatcccacca gcaagccgct gaccgctcaa cttttcttaa ttgtgcaaca 11100cagcagagac
aacgagacat ttagagatgc gcttttaaac atagcagaac cagaaggacg 11160gtggttgcta
gacttgatta acattcttca gagcatagtg gtacaggaac gtagcctgag 11220tttggccgac
aaggttgcgg ccattaacta ctccatgtta agtttgggaa agttttacgc 11280gcgtaaaatt
tacaagaccc cttacgtgcc cattgacaaa gaagtaaaaa ttgatagttt 11340ttacatgaga
atggccttga aagtgctaac cctcagcgac gacttgggca tctaccggaa 11400cgatcgcatt
cacaaggcgg tcagcgccag ccgccgtcgg gagttgagtg acagagaatt 11460gatgtacagt
ttgcagcggg cgctgacggg aactggacac ggacaggatg aaaatctctt 11520tgacgctggg
gcagatttaa agtggcaacc cagtagaagg gcgtggcagg cagccggtac 11580ctatttagaa
agcatagagg aggacgaaga cgaagacccg gagaacgagc ccattgacta 11640gccaattttt
ttagatgcaa aggcccgcgg cgatggcttc caccgaaacc gaacctatgg 11700accccgttgt
tcgggcggct ctccaaagtc agccctcggg tgtggctccc tcggacgatt 11760ggtctgctgc
tatggaccga ataatggctt taactgcccg aaattctgaa gcgtttcggc 11820agcaacccca
agcgaacagg ttttcggcaa ttttggaagc cgtggtacct tctcgtccta 11880atcctacgca
tgagaaagta ctggccatcg taaacgcttt agctgaaaac cgagctattc 11940gccctgatga
ggcaggccag atatacaacg ctctgctgga gagagtggcc agatacaaca 12000gcaccaatgt
tcagagcaac ctagaccgtt tggtgaccga cgttagggag gcggttgccc 12060aaagggagag
gttccacaaa gacgccaatc tggggtccat ggtggctttg aatgcctttc 12120tcagttcact
tccagctaac gttccgcgag gtcaggagga ctacactaac tttatcagcg 12180ccctccgtct
catggtagcc gaggtgcctc aaagcgaggt ttacatgtcc ggacccagtt 12240actattttca
aacttccagg cagggcttac aaaccgtaaa tttgtcccaa gctttcaaaa 12300acttggaagg
tctgtggggc gtaaaagctc cattaggcga ccgggctacc gtttccagtc 12360tgttgacgcc
taacacccgg ctgttgctcc tgctaatcgc tccgtttact gacagcggga 12420gcatttcgcg
ggactcgtat ttgggtcatt taataacttt gtaccgagaa gccattgggc 12480agtctcgcgt
ggacgaacac acgtatcagg aaattacaga tgttagtcgc gccatgggtc 12540aggaggacac
ttctagtttg caagctactc tgaactactt gcttaccaat cgtcgtcaga 12600gaatcccccc
acagttttca ctgtctccag aggaggagag aatccttaga tacgttcagc 12660agtctgtcag
tttgtattta atgagggaag gggacggccc cagtgctgct ctggacttaa 12720ccgcacgaaa
tatggaaccc ggtctgtact ccactaaccg ggctttcatt aaccgtctga 12780tggattatct
gcaccgcgcg gcggcgctta atcccgaata ctttaacaac gccgtgctga 12840atccgcactg
gctgccgcct ccgggctttt acacgggaga gtttgacttg cctgaagcaa 12900atgacggctt
tatttgggac gacgacacta gtgttttttc gcccatgcaa aagaaagaag 12960gaggagacgc
ccagagtcaa cgggtttcct tagccagcat gggcgcctct gtagcgagtc 13020ccctgcctag
tttttcgtcg gcttccagcg cggccggacg cgttaatagg ccccggctgt 13080ctggggaaac
ggattattta aatgatcctc tcatgcgtcc cgctcgggca aaaaattttc 13140ccaacaatgg
gatcgagagt ttggtagaca aaatgtccag atggaaaact tacgcgcagg 13200agcagaggga
gtgggaggaa cagcaaccgc gacccctaat tccccccaca cgtggtaacc 13260gtcgccggcg
tcaggatatg gggccctatc gcgtacccgt ggatcccgaa gactcggccg 13320acgacagcag
cgttctagat ctggggggaa gtggcaaccc ttttgcgcat ttacgcccgc 13380agggcagaat
aggcaagtgg taactaaata aaatacttac caaggccata gcgtggtgtg 13440cgtcctgttt
tttctagcgc gatgctccga cgtggaatac ccccggtggc cgttgcggaa 13500ggtccaccgc
cgtcttatga gagcgtgatg gcagcggcgg cgttgcaggg tcctttggta 13560gctccttatg
tgccgccgcg gtacctaggg cccacagagg gaagaaacag catccgttac 13620tcggaattgg
ctcctcttta cgacaccacg cgtctttatt tggtggacaa caaatcggcc 13680gatattgctt
ctcttaacta tcagaacgat cacagtaatt ttctgaccac cgtggttcag 13740aataacgatt
atacccccgc cgaagccgga acccaaacga taaactttga cgaccgttcc 13800cgatggggag
gggaaatgaa gactattttg cacaccaaca tgcccaacat taacgcctat 13860atgtttacaa
ataagttcag ggctaaatta atgacggccc atgaaactga caaagatccc 13920gtgtacgagt
gggtagattt ggttctccct gagggaaact tttctgaaac tatgactata 13980gatttgatga
ataacgctat agtggatcac tacttactag taggacgtca aaatggagtg 14040aaggaaagcg
agataggagt gaaatttgac accagaaact ttcggctcgg ttgggatccc 14100gaaacccagc
tggtaatgcc cggagtgtac actaacgagg cgttccaccc cgatattgtt 14160ttgcttccgg
gctgcggggt ggactttacc aacagcaggc tcaacaatct tctgggcatt 14220cgcaagcgcc
agccgtttca ggaaggtttt caaatcttgt acgaagacct cgtcggcgga 14280aatatccccg
ccctcctaga cgtcaccgct tatgaaaaca gcacgccggg ccaaccgccc 14340acaattcagc
ccgttacgga ggacgctaaa aaccgaagct ataacgtgtt acctggaacc 14400aacaataccg
cttatcggag ctggtacctc gcttataatt acggagacga cacgggtata 14460cgttcctcca
ctttactgac agcgcccgat gtcacctgtg ggtcggaaca gatttactgg 14520tcaatgcctg
atatgatgca agacccggtg acctttagga gttcccaaca gaccagcaac 14580ctgcccgtcg
tgggcacaga gttgcttcct atgtacgcta aaagttttta caatgatcaa 14640gcagtttatt
ctcagcttat tcgtcagtct accgctctta cccacgtgtt taatcgtttt 14700cccgaaaatc
agatactggt gcgaccgccc gcccctacta tcaccaccgt tagtgaaaac 14760gttcccgctc
ttacagacca cggaacgctg ccgctgcaaa acagcatccg gggagttcag 14820cgagtgacca
tcactgacgc caggcgccgt acctgtcctt acgtgtacaa agctttgggt 14880gtagtggctc
ccaaggtttt atcaagtcgc actttttaag acaatgtcca tccttatctc 14940acctagcaac
aataccggtt ggggtcttgg cgtgaataaa atgtacggag gagccaaaca 15000caggtcaacc
cagcacccgg tgcgggtgcg tggtcattac agggcaccct ggggcgcata 15060caagcgcaac
agacgggtag ccgaacgcac taccgtggac gacgtaattg actccgtggt 15120agcggacgca
cgcaactacg tgcccccagc cgttcccgct gccgctgcat ccacagtgga 15180tgcagttata
gatagcgtgg tggcagatgc aagagcctac gctcgtcaga agcgcagaca 15240acgacgagcc
cgtcgttcct tggctcgacc taccgcggcc atgcgcgccg cccgaaacct 15300gcttcgaagg
gcaaggcgca ccagcacacg cgccatggcg aggcagatta gggccggtcg 15360gaccagacga
agggcggcgc aacaggccgc ggcggccata gccagccttg cggcgcccag 15420aagaggcaac
gtttattggg tccgtgacgc cagcggagtt agagtgcccg ttcgtactcg 15480tcctgcgcgc
gtgtgattaa aagaaaaaat aaaaaccgca tccaacgctt aaaagtgaag 15540actgagtgtc
ctgttatata ttcagcgtcg gcgccatgac caaacgcaaa ttcaaggagg 15600agctgcttca
ggccattgca cctgaaatct atgccccgct aacggatccc gatgttaaac 15660ccgacgtgaa
gcctcgccgt ctaaaaaggg ttaagaagca ggagacaaaa aaagaggaag 15720cattagacac
cgagggggtg gagtttgtgc gttcttttgc tccccgaaga cgcgtgcaat 15780ggaaaggcag
acgcgtacgc cgccttctta ggccggggac cgcagtggtt tttaccccgg 15840gagagcgctc
ctcccgcact tacaagcgtt cgtacgacga ggtctacgcg gatgaggata 15900ttttggaaca
ggccctggag cagagcggag agttcgccta cggcaaaaga gcccgaaatg 15960aagttgctct
tcccctggac gaaagcaatc ccacccccag tttaaaaccg gtgactctgc 16020agcaggttct
tcccgtccaa agcacgggag aaagcaaaag gggaattaaa agagaggcag 16080tggagctgca
acccaccatg caattaatgg tcccaaaacg tcaaaagttg gaggatgtcc 16140tggatttaat
gacggtggac ccttcagtac aacccgacgt aaaaattagg cccattaaag 16200aagtggctcc
cggtttggga gtgcaaacgg tagacattca aattcccgta gaaagcatgg 16260atgtggaaaa
gccgaagccg accgccgtgg acatggcagt gcaaaccgac ccctgggccg 16320gtgctcccgt
tagagccgca agcgccattc gcaaccgccg ccgctacggt cccgccagtt 16380cgctcatgcc
agattacgct ttgcatcctt ccatcattcc cacgcctggt tatcggggac 16440aggtctttcg
cagacgatac tccgccccag ctagacgctc tactaggcgt agacgcagaa 16500ggcggacgac
tctccccgtc agagtaaggc gcgtaaccac gcgtcgagga cggacattaa 16560ctctccccac
agtccgttac catcccacga ttgtttaaca cgtacccacc tactttacag 16620atcatggccc
taacctgtcg tctccgcatt cccgttcccg gttaccgagg aagacgccgc 16680cacgggaagg
gcttcagggg tagcggttta acccgacatc ggcgtcggcg ggccgtgcgc 16740ggacgcatga
aggggggcat tctccctgct ttgattccta ttatagccgc ggcaatcggc 16800gctattccgg
gaattgcctc agtggccgta caagcctccc aaagacaata attaaaccca 16860ggcgccgctg
tctttcttac gcagtgtatt atggaagacg tgaatttttc gtccctggcc 16920ccgcgacatg
gtacccggcc ctacctgggc acttggaacg atatcggcac cagtcagctg 16980aacgggggcg
ccttcaactg gagtagcatc tggagcgggt tgaaaaattt tggttcaacc 17040ataaagtctt
acggaaacag ggcttggaac agcagcacgg gtcagctgct gcgcgataag 17100ctcaaagacc
agaattttca acagaaggtg gtagacggct tggcggccgg cattaatggg 17160gtcgtagaca
ttgctaacca ggcggttcag cgcgagataa acaaccgtct agatccgcgt 17220ccagtagagg
aggagctacc cgctttagaa aggcaacctc agggcgaaaa gcgtccgcgg 17280cccgatttgg
aagaaacgct tgtaacggaa gaacctcctt cttacgagga agccgtaaag 17340ggagcgccct
cggtggctct taaaccggtc acctatccac tcacaaaacc cataatgagc 17400atggctacgc
cggttgggga cgctccaatg gtagtagacc ttcctccacc acccgcaggg 17460atgaccactc
caacggtccc cgttcccatt gctccgcccg tttcgcgtcc cgccatccgc 17520ccggttgccg
tggcaacacc ccgttatacg cgcacaaaca actggcaaaa cacactgaac 17580agcatcgtgg
gcctgggagt caaaactctg aaacgccgca gatgctacta ttaaacgctt 17640tttaaccctc
cgtcttgtgt atacgcctgt tgttgtcagt aaaagaagag ccgcggattc 17700gccgccgtcc
tcgcttgcaa gatggccacc ccatcgatga tgccgcagtg gtcgtacatg 17760cacattgccg
ggcaggatgc ctcggagtac ctcagtcccg gcttggttca gtttgctcga 17820gccaccgata
cctacttcac actgggaaac aagtttagaa atcccaccgt ggcccccacc 17880cacgacgtca
ctactgatcg gtcccagcgt cttactttgc gatttgtgcc ggtagacagg 17940gaagacactg
cctatgctta caaagcccga ttcaccctgt ccgtgggtga taacagagtg 18000ctggacatgg
ccagtaccta ctttgatata cggggagtaa tagaccgagg tcccagtttc 18060aagccgtatt
ccggtaccgc ttataatgct ttggctccaa aaggggcgcc taacaacagt 18120cagtggcaca
ccgttaacga ggacaaccag aatttcctga tgcacacata tgcccaggcc 18180ccatttgaga
gcgaatttgt ggctaacaac ggcaacattg gtattcaagt gggagtgagt 18240gacaccaaca
ctcccatttt ggcggatccg acatatcagc cggaaccaca ggacggagaa 18300ccgcagtggc
agagtctaaa agcgcaagag aagctagaac atgcagggag agcgctgaag 18360tataccactc
ccatgaaacc ctgctacggg tcctacgctc gccccaccaa cgcgcagggc 18420ggacaaggga
taattgacga acaaactgga gaaacagatg cgacggaaat tacccaaaac 18480tactttgcgc
tgtcaacggc gaccacggac ttcacgccaa aagtggtgct gtacacggaa 18540gatgtttact
tgcaaacccc agatactcat ttggtgtaca ctccgtcggc cacggaaggc 18600agcactcagg
atatgctggg ccagcaagcc gccccgaatc gccctaacta cattgggttc 18660agggacaact
tcattgggct aatgtactac aacagcaccg gaaacatggg agtgttggcg 18720ggccaggcct
cgcagctgaa cgcggtggta gacttgcaag accgaaatac cgaactatcc 18780taccagctca
tgctggatgc tctgagcgat cgcacaagat acttctccat gtggaatcag 18840gcggtagaca
gttacgaccc tgatgtgcga attatagaga atcacggggt ggaggatgag 18900ctccctacgt
actgttttcc actttccgga gtcggcatta ctcaagagta tcagggagtg 18960gaacccacca
atcccgccgc tgccgacatt acgtggaaag aggacgccac ggtctttgat 19020cctaattaca
ttgctaccgg caacatcaac gcctacgaaa ttaacttgca ggccagcctc 19080tggcgcagct
ttctttactc caacgtagct ctctacctac ccgacaagta caagtacacc 19140cctgctaacg
tcacactccc cacaaacact aacacctaca agtacatgaa cggccgcgtg 19200acctctccca
gcttagtaga catttttgtg aatgttggag cccggtggtc gccggaccct 19260atggataatg
ttaatccatt caaccatcac agaaatgccg gcctgcgtta ccgctctcag 19320cttttgggta
acggacgcat tgttcccttc cacattcaag taccgcagaa gtttttcgcc 19380attaagaacc
ttttgctgtt gcctggttct tacacctacg agtggtcctt cagaaaggac 19440gttaatatga
ttctccagag cacgcttggt aacgatctgc gaacagacgg agcggccatt 19500aggatcgaaa
gcgtaaacct gtacgcgaac ttttttccca tggcccacaa cacagcctcc 19560actttagagg
ccatgctgcg caacgacacc aatgatcagt ccttcaacga ctacctctcc 19620gccgccaaca
tgctgtaccc catcccagcc aacgcaacca atgttcccat ttctattcct 19680tctcgcaatt
gggccgcttt cagaggctgg agcttcaccc gtcttaaagc caaggaaacc 19740cctgcccttg
gatctggctt tgatccctac tttgtttact caggctccat tccttacctc 19800gacggcacct
tctatctcaa ccacactttt aaacgggtgt ctattatgtt cgattcctcg 19860gtgagctggc
caggaaacga ccgactcctc acccctaatg agtttgaagt taaacgggta 19920gtggacggag
aaggctacac tgttgcgcag agcaacatga ccaaagactg gttcctaatc 19980cagatgctta
gccactacaa catcggctat caaggcttct acattcccga gggctacaaa 20040gatcgcatgt
actccttctt ccgcaacttc caacccatga caagacaggc cgtggatccc 20100gtaaactaca
ctaattataa ggaaatcacg gtggctcacc agcacaacaa ctcagggttt 20160gtgggattca
tgggccccac catgcgcgag ggtcatccct acccagcaaa ctacccctat 20220ccgctcattg
gagacagtgc ggtgcctacc gttacccaga aaaagttttt gtgcgatcgt 20280accatgtggc
gcattccttt ctccagcaac tttatgtcta tgggcgctct taccgatctg 20340ggtcaaaata
tgctttacgc aaattccgcc cacgccctcg acatgacctt tgaagtggat 20400ccaatggacg
aacccacact actctatgtt ctatttgaag ttttcgacgt ggtccgtgtt 20460caccagcctc
accggggcat tatcgaagcc gtgtatttgc gtactccatt ctccgccgga 20520aacgccacta
cataagcaac atggggtcca gcgaagaaga actcaaagcc ataataagag 20580atttacggtg
tgcgccatat tttttgggaa cctttgacaa acgttttccc ggatttgtgt 20640cgccgcacaa
acttgcttgt gccattgtaa atacggccgg aagagaaacg gggggagttc 20700actggctggc
ttttggatgg aatccgaaaa accgaacttg ctacctgttt gatccgtttg 20760gcttttcgga
tgaaaaacta aaacaaattt atcaatttga atacgaaaac ttgctaaagc 20820gaagcgctat
cgcctctacc ccggatcgat gcgtgactct ggtaaaatcc acccaaactg 20880ttcagggacc
taactcggca gcttgtggcc tgttcgcctg tatgttcctg catgcttttg 20940taaactggcc
caatagcccc atggaaaata accccactat ggacctgata gtcggtgtgc 21000ctaattacat
gttaaaaagc ccccaggttc agggaacgct ttttaaaaat caacaagcgc 21060tgtaccgttt
tttagccacc cactcccctt actttagaca tcatcagcag caaatcgaaa 21120aggccacggc
ttttaataaa caaactgaat ccaaaaatta ataataaatt tttatgcttt 21180atttgtactc
cgtcgtattt tttttttcaa aattcaaacg ggttcatttc aaagtcaaca 21240tgggcagcgg
gaagagtgag gttacgatat tggtacttgg gatgccattt aaattcggga 21300accaccattt
tgggaagaac ggtatcggga agatgatcct gccaaaactg ccttacaagt 21360tgcaacgctc
caattacgtc gggagcagaa atcttaaagt cgcagtttgc ctggttgttt 21420gctttgctgt
tacggtgtag agcgttggcg cactgaaaca ccagaacgct cgggttgttt 21480acactggcca
acatggcgcg gtcgtgataa ccgaaatcca ctaagtcttc caagtgaata 21540ttctcaacat
ttaacgcaaa aggggtaatt ttgcaagttt gacgtcctcc acgggacatc 21600tcgggtcgcg
taaaacagtt acaacgaatg ggcatgagaa gatgcttgga tcccttcacc 21660atgtgagggt
agcaagcttg catgaaagcg gcaatttgac gaaaagcaat ttgcgccttc 21720gtcccctcag
aatagaacat accgcaggat ttattagaaa agttgttggg agagcacccc 21780gcatcaaaca
tgcaacaacg ggcatcctca tttcttacct gaactacgct acgaccccag 21840cggttctgaa
caattttggc cttggcgggg gtttccttta gagctctttg cccattttcg 21900ctagttacat
ccatttctat gatctgctcc ttcactatca tggtcaaacc gtgtaagcat 21960ttaagctcac
cctccacatc cgtacactga tgctcccaag ctacgcatcc ggtaggttcc 22020cacaatttgg
aatctacacc ggcgtacacc tgcacgtaag ccattaggaa gcggcccatc 22080agagaaatga
aacttttatg agaagtaaaa gtcaaggtgt tgtgcttata ctcctcattc 22140atccaagcct
ggcatatttt gcggtacacc tctccttgct cgggcaaaaa tttaaacgag 22200gaccttagct
ccttgtctac cttgtacctt tccattaaca taaccataaa ttccatgccc 22260ttttcccaag
cagaaaccaa cgggttagag gcagggttaa caacggttga actggttccc 22320tccttttgtt
gacgggctgc ggacattatg gggtgatttt cgtcgaattt ttcgaaggct 22380ttgcttccgt
ccgccttccg tactattttt acaggagggt agctgaaccc cacttccagc 22440aactctccca
cctcttcgtc gctgtcggcc accacttctg gtgaaggcgg gagaggcagt 22500gacttccgcg
ctttcttttt tgggggcaca gctggaactt tttcgggtgt tacttcgcga 22560cggtcctgat
tgctggccat tgttttttcc taggcaaaaa acatggaatt ggaaccagcg 22620gccgaaagca
acaacttaac ctccccccat ttttacgaga acaaggacgc cctcaccgag 22680gctacggggt
ccgcagtgga acaggacgtg ggctacgcgt ctccgccaga aacggcggag 22740gaggaaaagg
atgacaaaaa cttatcgagc ccacaaaaag acaagcaaca agatgataag 22800acacaggaaa
acgaggagga cgttagcttc catgacgatt acctaggcaa aggagaggac 22860gttttactaa
aacacattcg aaggcaaagc gccattgtgg aaaacgccat ttccgaaaaa 22920accgaaatac
cggtgtcggt gtacgactta agcctggcgt atgaacagag cctcttttct 22980cctcgtgttc
cacccaaaag acaacccaac ggcacctgcg agcccaaccc gaggctaaac 23040ttctacccgg
catttgccgt tcccgaagta ttagccacct atcatatttt ctttaaaaac 23100cacaaaatcc
ctgtttcctg ccgcgctaac agaagcgaag ccgatgccca acttttgctg 23160ggtccaggtg
cccgcatacc tgattttgct tccttagaag aagtgccgaa aatattcgag 23220ggcttgggag
acgaaaaacg tgctgcaaac gctctgcaag aaaacacaga aagtttcagc 23280gcgctggtag
agctcgcaaa tgacaacgcc cgtctagccg tgctcaaaag aagcgtagaa 23340gtcacccact
ttgcctaccc cgctgtcaac ttaccgccta aggttatgaa cacggtcatg 23400gactgcttac
tagtaaaaag ggcaaaacct ctgggggaag gggaacagga ggaagaagac 23460tcagacgagg
gcaaacccgc cgttaccgac gaagaactct cacgctggtt gcgcacaaca 23520gacccagcag
agttagaaaa tcgtagaaaa cttatgactg cggtcatact ggtaaccgcg 23580gagctggagt
gcctcagtag attttttacc gatacggaaa ccataaggaa agttgaggaa 23640accttgcatt
acaccttccg tcacggttac gtgaaacaag cctgcaagat ctctaacgta 23700gaactcagca
acctggtttc ttacttaggc attttgcatg aaaacagact gggtcaaaac 23760gttctccacg
ccacgctaaa gggagaagcg agaagagact atattaggga ctgcgtctac 23820ctgtttttgt
gttttacgtg gcagtccgca atgggggtct ggcaacaatg cctggaagat 23880gacaatttgc
gagagttgca aaaaatactg aatagagaac gaagggacct gtggacgggt 23940tttgatgaaa
ggacggtagc caaggaccta gcgaacatta tttttcctag cagactagta 24000agaactttgc
aaaatggctt gccagacttt atgagccaaa gcatgataca gaacttccgc 24060tccttcatct
tggaacgctc aggcattctg ccttccatga gctgcgcttt gccttcagat 24120tttatccctt
tgaccttcag ggaatgccct cctccactct ggagccactg ctacttattc 24180caacttgcaa
acttttttgc attccattct gacgtcgtgg ccgacgttac cggagaggga 24240ctgatggaat
gtcactgtcg gtgtaatctg tgcacccccc accgttccct ggtttgcaac 24300accgctttgc
taaacgaaac ccaggtaata ggtacctttg aaatccaggg accttcagaa 24360tccaacaaag
gagccgcggg gttaaaacta actccgggat tgtggacttc cgcctaccta 24420cgcaaatttg
taccggtgga ttaccacgcc cacgaaattc gattctacga agaccaatca 24480ggacccccca
aagcagagct cagcgcttgc gtcattactc aaagcagcat tgtggcccaa 24540ttgcaagcca
tcaacgaagc ccgccgaaac ttccttttga aaaaaggaaa gggggtatac 24600ttggaccccc
aaacgggcga agaattaaac accaccccct ccccagttgc aggtgtctcc 24660cacaatgcca
ccaaagaaga ggtccgccgc cctcccgctc tccaaagcag tcacagcaaa 24720gcgacccaaa
cagaggaaag cccaggagac cgaggaacca tggagcgagg aggaggactg 24780ggagagtcag
ggagaggaag acatggaaga ggaatgggac agcctagcca gcgacgaggg 24840agaggcagag
gcagagacag aggaagcatc cgtcgcaaaa ccctcactgg cgaaacgagt 24900ttcaaacgtt
actacgacct cagatcagcg cacagtcagt cgtagatggg acagtaccaa 24960cgccgccccc
gccggtaaga ccctttcgtt ggcaaaaccc cgacagggat accgctcctg 25020gcgagcgcat
aagaacgcca ttataaactg ccttgaaaat tgcggaggca acatttcttt 25080cacccgtcgg
tttatgctct ttcgaaacgg aattgccatt cccagaaacg tcttacatta 25140ctatcgtcat
tcttacagcc cctcgaaaac cgtacctctc ggcagcggcg gccgcggcgg 25200acactaaaaa
gaggttacct aagcagaaca aaaagcaagt gaaagagccc ccatctacca 25260aagaacttag
gaaccgaatt tttcctactc tgtatgccat tttccagcaa agccgcggac 25320aagaaccaga
gcttaaaata aaaaaccgct ctctccgttc acttacccgc agttgtctat 25380atcacaaaaa
cgaagaacag ttgcaacgca cgttggacga cgcagaagct ctgttcaaca 25440agtactgcgc
agcaactctt aaagaataaa aaaaatcgcg ccaaaaattc aaaaaagatt 25500gtgtcatctt
ggctaacggc ccgcaatgag caaagaaatt ccaacccctt acatgtggag 25560ctaccagccc
cagatgggat tggccgcagg tgcggcccaa gattactcaa ccaaaatgaa 25620ctggttaagc
gccggccctc acatgattgc tcaagttaat ggaattcggg cccaccgcaa 25680tcaactgtta
ctggaacagg ctgctcttac caccacaccc agaaatcaat taaaccctcc 25740cagttggcct
gcgtcactgg tgtaccagga aacaccggct ccgacaaccg tactacttcc 25800tcgtgacgcc
caggccgaag tcctcatgac taactcaggt gcacagctgg ccggcggggc 25860gtgccggtat
cggtccaaag gccccactgg gctctccgcc cctttgggta taaaaagggt 25920gctcatccgt
ggcagaggca cccagctcaa cgacgagaca gtgagctctt cgcttggtct 25980acgaccagac
ggagtgttcc agctcgcggg ctcgggccga tcctccttta cgcctcgcca 26040ggcttatttg
actctgcaaa gttcttcatc tcaacctaga tctggtggca ttggaacgct 26100tcagtttgtt
gaagagttca cgccatcggt ctacttcaac cccttctccg gggcgccggg 26160gctgtatccg
gacgagttca ttccaaactt cgacgcggtg actgactccg tggacggcta 26220cgactgatgt
ccaatgagtt tgagtctcta gtagaccaag ctcgtatccg ccacctcgac 26280cactgccgtc
gccaccggtg cttcgtcaga gaacatctcc agaccgtcta ctttgagcac 26340ccagaaagcc
accccgacgg tccctgtcac ggtatttacg tgattgtgga cggatcctgc 26400gacacccacc
tcgttcgcta ctacagccaa cgccctctat tggtggaacg ccaaaccggc 26460gtcactaaga
ttaccctcac ctgcatctgc tcgcaacccg gcttacatgc agacctctgc 26520tgccatctgt
gtgctcgctt taatcagctt cgttagctgc gttcagcctg cctccgggca 26580gattgacgtc
tgccaagcgg ctaacgtgac tgttaccgac ctctcaaaac ccacaatcac 26640cgttaagtgc
ggcttctaca acaaaccagt ttctacagtt ttctggtact tcaacaacac 26700cctcttctcg
tccttcaatc cgttttcact ccttatcagc aacatcaagc aaccctttaa 26760ctactacacc
accggcaaca gtcttcagct ctttgctccc tacagttctg gacgttacca 26820ctgcgaagtc
cttaagtgca ctcaacattt tttcattgga attaaacctg caactccaat 26880caccactgcc
gctaccacta ctacccctaa tactactgct gtcactactc ctcctcctgc 26940tactgcatct
tctactacaa ctcctccagc cgccgccacc acttcttctc ccagcgctcc 27000caagagatcc
atcagatcct tctcccacag ctttctgagt atcaacgtct cagatcccac 27060tcaagtcctt
cagtgcccct gctccggcaa ctacactttc tggggcgtaa acggaactga 27120ttgggccttt
gttcagaaca tcacctttgt tacctttatt cagaaccaaa ctatcaactt 27180caaccacaag
ttcctcaaca cttctctgaa cctccgactt ccagttgttc ctggtaacta 27240cagctgcgac
actcaaagcc gtcagtgcca gcacgttttt accgttaccg ttatttaccc 27300cactcccact
actccggctc caccgaccac cgccaccgaa actaacaccc accaggcctt 27360ttttgctccg
agcgaagctc cagaaacagc ggttgcctcc actccttggt ggctatttgt 27420tgtggttggc
attgttgtgg tgattattgc aggtgcagtt acagcctttt ttatttacaa 27480gaagcaccca
gaagtggtgg ttttctttca cagagttccc acctcagttt actaaggtaa 27540gatgaaattt
ttactgttta ccatcctttt tagcctttgt ggctcttctc actcagtttt 27600ttatcctcct
ccaaattgct acgttacctc cagatgggat cccaactgcc acattcaaat 27660cctgtgccct
gacaacagca ccatttacta ctccaatacc tccgtggtcg gctctctcac 27720actcaaccct
gaggataacc cacccgacca ctatctcatt aatcacaccc tgtcaaatgg 27780caaaactgcc
ctttacaatt ttacttttcc catggccact ctgtgcacca tcactgaagc 27840cacagattca
ggctacgatt ttactgtttt gtttttactt ttaatggtgg ttgccctcat 27900tctccttttg
gcagcacttg cttgtctctt ttaccactac tgccgctggt ggcgtaaggg 27960atcctacacc
ttaccccacg accagcgcag tatccaccta gaaatttaac aaacttttcy 28020tttttttttt
gcagtatgac tcttgctctt cttatctgca ctcttacagt gccagtcacc 28080cttgccaccg
tctcttttgc cacggctact catctcgaac cggaatgcct tccaccattc 28140caagtttacc
ttgtgttttc ttttctgtgc tgcacctgta ttgctagcct cattacttta 28200ctgctggtat
tttttcagtt tgtggactat ttcctagttc gcctgcgcta tcgtcaccac 28260gcaccgcagt
tccaaaatcc caacgttgct cgactcttag ctcttcaacc atgaaagctc 28320ttctggtgct
agcattttta cccctcactc actgctgccg ttttacattc tccaagctgt 28380ggaccatcag
agactgttac ccctttgttc cagtccgtga agaaccatgg ctgtttacta 28440tcctcatcgt
cgctgccctt attgcctttt ttgcagctat ttacctgaga aatatattac 28500ctttctcttg
gaatacagat gatctacttg attatcccat tctcccccaa cccaacgtta 28560ttcctttgca
aaaccttctc cccaacctcc ctgaccttct ggatcaactt ccccctaatc 28620ctgatccacc
ccgttccccc tctacctgca gttacttccg cttcaccaat gagtaacccc 28680ctagaaattg
acggactgcg gtccgaacaa caagccctca tggtacgtga gcgggccaga 28740caacgggagc
taaagcacca ggagctgtta gatctgcaaa acacccatca gtgcaagagg 28800ggcattttct
gcgcggtgaa gcaggcttct cttcgcttcg aaatgctgaa ccctccagac 28860cacgagctcc
aatacaccat tcagcaagag cgccaaaact gtgtgtttat ggtgggctct 28920aaacccatca
aaatcacaca aagtagaggg gaggttaccg gggctctccg ttgttcttgc 28980acccattccg
aatgcatgta cacccttgtg aaaaccctct gcgggttaca tgatttaata 29040ccctttaatt
aacagcaaaa ccaatcaaac ccaatcaaca cccaattata aaaatgaaca 29100ataaacttac
atgaattcag cagttaactt gtttgtggct tttgtgtcca atttaaccca 29160tttaccctct
tcccaactct gatatccaat acttcttcta ctagcaaact ttctccatac 29220cctaaagggc
atgtcaaatt taacaacttt gccactgcta tctattatat tcattttaga 29280tgaagagagc
cagagctgta acagaagact tcaaccccgt atacccttat gacaccccta 29340ccggtggaaa
cgtcgcaccc tttgtaactc cgccttttgt gtcccctgat ggtctacaag 29400aaagcccccc
tggcacactc tccctaaaca tcaaatctcc cctcactatt acaaaccacc 29460aactagacat
taaattggga agtggactat cagtatcttc aaagggagaa ttagaagcca 29520gttccaccac
caccgtaact gcgcccctaa ccaatacaaa caacattata ggactttctt 29580attctgatgg
cctgacttta gaacagaatt ttctgaaagt aaatcttgga agcggtctca 29640cgtttgataa
ccaaagtata accctcaacc ccccaactct gtggacgggc ccggctgcag 29700aaccaaacgc
cactgtactc cccccaggca gcgcagacat tcctgattac aacgcatgca 29760tcaccctgag
tttaactaaa ataggacccc tggtaaatgg tttaatttcc cttataggga 29820tttcagcccc
cctaactccc atagcggcag acgtgaactc ggtgaaggtt tccttacttt 29880ttaatgacaa
tggtcaactc atcgggccag actttgaaac tgacactttt ggatttaaag 29940tgggtaacac
tatagacaca acttccaccg ccagcagggt tcctttcatg cccaatgtca 30000ctacttatcc
tcataactcc acaggtcaag ctggagcagg gcattatatt attgtgccgg 30060gaatggttaa
cgccgactct tccaaaccct gcaacttaat tgtgggactt aacacagcgg 30120gatcttcggg
attctccatt acattggagt ggacagggct ggctaattac aacctatccc 30180ttggtacctc
cacctttttt ttagttattt atcacaagac caaaattaaa gtgcataaaa 30240agttttattt
gcgttgattc atgttacagg gggacgggca tcgtacacct tgtaggggat 30300tgcacagcca
tacaccatca atttcctcag ccatctttgt cttcttactt ctgttttgct 30360gcaacacaaa
ggagccttga attcctctaa aattatcttc acagttttaa gcaatatcct 30420tctagttctc
ctggcacagc accttaccct aatctcgctt aaatcccaac agtaagtgca 30480acataaaatt
atcatattat taatatgccc gtaggtaaac cgcccccacc caaaactaat 30540cttttctaaa
gctgcagcag catgtatgtc atgttttact ttcaaccaaa ttaaatgcct 30600ccccctaaca
tatgaacttc ccacataata cacctctttg ggcattttaa agttaacaat 30660ttccctgtac
cacagaaatc tctgatttat taaagctcca tacaccaaca tataaaacca 30720tttagccaac
agcacccctc cagctttaca ttgaagcgat cctggttttt cacaatggca 30780atgtaaagtc
cacaactcat aaccatgcag cacttcagat cttctcaaat caatactagc 30840gcagcaatca
cacaccttca taaaattttt aagaatgttc atttcatagt tagttagaat 30900catgtcccaa
ggaacaggcc attccagcaa caccgccagg gccgcacagc acggaagact 30960gcgcacaaca
gctacactgt gcatggtgag agaactacat tcaggtaagg ggcacgagta 31020ggcgagggga
gatgcagcag tcacacgccc ttcagacggg ggcagcatat gatggtgata 31080aggactcaac
ctgcagaaga atcttctgac gcgcggggcc atcccacatt aactcacgtc 31140gcgcttcttc
gtacttgaag tagcaaaacc aggttctttg ataacacact tcccgccgat 31200gaggatcctt
tctcttctgg tgttcactgc gccaagcata gaacagaaac tcacgcaaac 31260tggttaccag
ttcttcagca ggaggagtaa actctacaga aaagcgacgg taattttgaa 31320gatgttcagc
tactgtaaca taagctaagc ccatccaaga tatgcatgca gaccgatccc 31380tgaaaactgt
aggagcagaa agagccggta gcaccatgga gactattcca aacgatctgg 31440cagaatttca
aaatgcagat ctcgaagatg acaacgatct ccaccgctac cctgatgata 31500acgaacagcc
aggtcaaaaa caatactgtt ttccaaattc tccaccgtgg cattgatcag 31560atcagcaatt
cgcacttcca caaaaagaag gatagcaaac gcctgaccct gcagatgttc 31620tatagccaga
gtagcatttt gaaccatgcc cagataattt tcatttttcc agtcgcgaat 31680aatctccaca
agaagagctt ccagattcat cccatgagca ttaaaaagct cccacagcgc 31740gccctcaatg
tacatccgca ggcacacctt catgattact gtagcagctc cgcctcctga 31800gacacctgca
gtaaattaac ccggcttaaa tcaggatcta ctccccgaca tcgaagcttc 31860tggcgtagcg
aaagttgaag atattcagca aagtccgaaa ccaccaaagc agtgttttcc 31920tcgccaggct
gcaactcagc agtggcgacg gagcaaaaca cacgaagaca gggagcaagc 31980tgaaccacag
tagcgcccca gaagcatagc tgttgaggag gagtgtaata atccatgcag 32040tgataccaaa
agtaagagca ttcctgacgc aaaaagccaa gcacgtctat attaagctca 32100tgcaaataat
ccagcaaagc ttgaggcacg gtgacggaca cccaaaccgg gcgatgagca 32160aacatgctta
ccctggaaaa gagaacacat taaacttgcg tggcttcaag cacagtagga 32220taaatcacac
gatgcaaaag aaaccttccc accgcttgac cacgttggcc atgataaaaa 32280tcgggagtgt
gattgaaaag caataacttc aactcccatc tagtgcaggg atccacagta 32340tcggctcctg
caaaaatccc ccgcctcaca agatccccca aaggtcccaa acggccgata 32400tatcccggag
gcacttgcac tctaatctgc aagtacaaca gcaacacccc ctcaggggga 32460attacaaaat
cctcaggaga gaaaagagtg tataccccag aatagccttc ctgaacaggc 32520aatatgccat
gttcaccctc ccggtaaaca tacaaaaact cttcattggt agccatacca 32580aaagagaaca
gcacaggctc agcagcgtcc agaaatgttc tgcgccgcta actgagctcg 32640ctctgccttt
atactgaaaa atactgacgt caataaccac ttaacacaaa gttcagacct 32700atttttaatt
attgagtttc acttccgcgt tccgtttccg cgttcttcgc tgacgcatta 32760aacgcgccac
tccctcccac aattcagcgc ggctcgtgag taatctgtta actgcgcgcc 32820ccgcccgaac
cgcccaccgg cccgcccatt gacgtcacgg ccaatcacag ttgtggacac 32880gcccatctca
tttgcatatt aacttctgtt tacattgtaa ggtatattat tgatgatg
3293817129PRTArtificial SequenceSynthetic polypeptide 17Met Phe Ala His
Arg Pro Val Trp Val Ser Val Thr Val Pro Gln Ala1 5
10 15Leu Leu Asp Tyr Leu His Glu Leu Asn Ile
Asp Val Leu Gly Phe Leu 20 25
30Arg Gln Glu Cys Ser Tyr Phe Trp Tyr His Cys Met Asp Tyr Tyr Thr
35 40 45Pro Pro Gln Gln Leu Cys Phe Trp
Gly Ala Thr Val Val Gln Leu Ala 50 55
60Pro Cys Leu Arg Val Phe Cys Ser Val Ala Thr Ala Glu Leu Gln Pro65
70 75 80Gly Glu Glu Asn Thr
Ala Leu Val Val Ser Asp Phe Ala Glu Tyr Leu 85
90 95Gln Leu Ser Leu Arg Gln Lys Leu Arg Cys Arg
Gly Val Asp Pro Asp 100 105
110Leu Ser Arg Val Asn Leu Leu Gln Val Ser Gln Glu Ala Glu Leu Leu
115 120 125Gln18116PRTArtificial
SequenceSynthetic polypeptide 18Met Lys Val Cys Leu Arg Met Tyr Ile Glu
Gly Ala Leu Trp Glu Leu1 5 10
15Phe Asn Ala His Gly Met Asn Leu Glu Ala Leu Leu Val Glu Ile Ile
20 25 30Arg Asp Trp Lys Asn Glu
Asn Tyr Leu Gly Met Val Gln Asn Ala Thr 35 40
45Leu Ala Ile Glu His Leu Gln Gly Gln Ala Phe Ala Ile Leu
Leu Phe 50 55 60Val Glu Val Arg Ile
Ala Asp Leu Ile Asn Ala Thr Val Glu Asn Leu65 70
75 80Glu Asn Ser Ile Val Phe Asp Leu Ala Val
Arg Tyr His Gln Gly Ser 85 90
95Gly Gly Asp Arg Cys His Leu Arg Asp Leu His Phe Glu Ile Leu Pro
100 105 110Asp Arg Leu Glu
11519121PRTArtificial SequenceSynthetic polypeptide 19Met Val Leu Pro Ala
Leu Ser Ala Pro Thr Val Phe Arg Asp Arg Ser1 5
10 15Ala Cys Ile Ser Trp Met Gly Leu Ala Tyr Val
Thr Val Ala Glu His 20 25
30Leu Gln Asn Tyr Arg Arg Phe Ser Val Glu Phe Thr Pro Pro Ala Glu
35 40 45Glu Leu Val Thr Ser Leu Arg Glu
Phe Leu Phe Tyr Ala Trp Arg Ser 50 55
60Glu His Gln Lys Arg Lys Asp Pro His Arg Arg Glu Val Cys Tyr Gln65
70 75 80Arg Thr Trp Phe Cys
Tyr Phe Lys Tyr Glu Glu Ala Arg Arg Glu Leu 85
90 95Met Trp Asp Gly Pro Ala Arg Gln Lys Ile Leu
Leu Gln Val Glu Ser 100 105
110Leu Ser Pro Ser Tyr Ala Ala Pro Val 115
12020287PRTArtificial SequenceSynthetic polypeptide 20Met Ala Pro Arg Val
Arg Arg Phe Phe Cys Arg Leu Ser Pro Tyr His1 5
10 15His His Met Leu Pro Pro Ser Glu Gly Arg Val
Thr Ala Ala Ser Pro 20 25
30Leu Ala Tyr Ser Cys Pro Leu Pro Glu Cys Ser Ser Leu Thr Met His
35 40 45Ser Val Ala Val Val Arg Ser Leu
Pro Cys Cys Ala Ala Leu Ala Val 50 55
60Leu Leu Glu Trp Pro Val Pro Trp Asp Met Ile Leu Thr Asn Tyr Glu65
70 75 80Met Asn Ile Leu Lys
Asn Phe Met Lys Val Cys Asp Cys Cys Ala Ser 85
90 95Ile Asp Leu Arg Arg Ser Glu Val Leu His Gly
Tyr Glu Leu Trp Thr 100 105
110Leu His Cys His Cys Glu Lys Pro Gly Ser Leu Gln Cys Lys Ala Gly
115 120 125Gly Val Leu Leu Ala Lys Trp
Phe Tyr Met Leu Val Tyr Gly Ala Leu 130 135
140Ile Asn Gln Arg Phe Leu Trp Tyr Arg Glu Ile Val Asn Phe Lys
Met145 150 155 160Pro Lys
Glu Val Tyr Tyr Val Gly Ser Ser Tyr Val Arg Gly Arg His
165 170 175Leu Ile Trp Leu Lys Val Lys
His Asp Ile His Ala Ala Ala Ala Leu 180 185
190Glu Lys Ile Ser Phe Gly Trp Gly Arg Phe Thr Tyr Gly His
Ile Asn 195 200 205Asn Met Ile Ile
Leu Cys Cys Thr Tyr Cys Trp Asp Leu Ser Glu Ile 210
215 220Arg Val Arg Cys Cys Ala Arg Arg Thr Arg Arg Ile
Leu Leu Lys Thr225 230 235
240Val Lys Ile Ile Leu Glu Glu Phe Lys Ala Pro Leu Cys Cys Ser Lys
245 250 255Thr Glu Val Arg Arg
Gln Arg Trp Leu Arg Lys Leu Met Val Tyr Gly 260
265 270Cys Ala Ile Pro Tyr Lys Val Tyr Asp Ala Arg Pro
Pro Val Thr 275 280
28521325PRTArtificial SequenceSynthetic polypeptide 21Met Lys Arg Ala Arg
Ala Val Thr Glu Asp Phe Asn Pro Val Tyr Pro1 5
10 15Tyr Asp Thr Pro Thr Gly Gly Asn Val Ala Pro
Phe Val Thr Pro Pro 20 25
30Phe Val Ser Pro Asp Gly Leu Gln Glu Ser Pro Pro Gly Thr Leu Ser
35 40 45Leu Asn Ile Lys Ser Pro Leu Thr
Ile Thr Asn His Gln Leu Asp Ile 50 55
60Lys Leu Gly Ser Gly Leu Ser Val Ser Ser Lys Gly Glu Leu Glu Ala65
70 75 80Ser Ser Thr Thr Thr
Val Thr Ala Pro Leu Thr Asn Thr Asn Asn Ile 85
90 95Ile Gly Leu Ser Tyr Ser Asp Gly Leu Thr Leu
Glu Gln Asn Phe Leu 100 105
110Lys Val Asn Leu Gly Ser Gly Leu Thr Phe Asp Asn Gln Ser Ile Thr
115 120 125Leu Asn Pro Pro Thr Leu Trp
Thr Gly Pro Ala Ala Glu Pro Asn Ala 130 135
140Thr Val Leu Pro Pro Gly Ser Ala Asp Ile Pro Asp Tyr Asn Ala
Cys145 150 155 160Ile Thr
Leu Ser Leu Thr Lys Ile Gly Pro Leu Val Asn Gly Leu Ile
165 170 175Ser Leu Ile Gly Ile Ser Ala
Pro Leu Thr Pro Ile Ala Ala Asp Val 180 185
190Asn Ser Val Lys Val Ser Leu Leu Phe Asn Asp Asn Gly Gln
Leu Ile 195 200 205Gly Pro Asp Phe
Glu Thr Asp Thr Phe Gly Phe Lys Val Gly Asn Thr 210
215 220Ile Asp Thr Thr Ser Thr Ala Ser Arg Val Pro Phe
Met Pro Asn Val225 230 235
240Thr Thr Tyr Pro His Asn Ser Thr Gly Gln Ala Gly Ala Gly His Tyr
245 250 255Ile Ile Val Pro Gly
Met Val Asn Ala Asp Ser Ser Lys Pro Cys Asn 260
265 270Leu Ile Val Gly Leu Asn Thr Ala Gly Ser Ser Gly
Phe Ser Ile Thr 275 280 285Leu Glu
Trp Thr Gly Leu Ala Asn Tyr Asn Leu Ser Leu Gly Thr Ser 290
295 300Thr Phe Phe Leu Val Ile Tyr His Lys Thr Lys
Ile Lys Val His Lys305 310 315
320Lys Phe Tyr Leu Arg 32522127PRTArtificial
SequenceSynthetic polypeptide 22Met Ser Asn Pro Leu Glu Ile Asp Gly Leu
Arg Ser Glu Gln Gln Ala1 5 10
15Leu Met Val Arg Glu Arg Ala Arg Gln Arg Glu Leu Lys His Gln Glu
20 25 30Leu Leu Asp Leu Gln Asn
Thr His Gln Cys Lys Arg Gly Ile Phe Cys 35 40
45Ala Val Lys Gln Ala Ser Leu Arg Phe Glu Met Leu Asn Pro
Pro Asp 50 55 60His Glu Leu Gln Tyr
Thr Ile Gln Gln Glu Arg Gln Asn Cys Val Phe65 70
75 80Met Val Gly Ser Lys Pro Ile Lys Ile Thr
Gln Ser Arg Gly Glu Val 85 90
95Thr Gly Ala Leu Arg Cys Ser Cys Thr His Ser Glu Cys Met Tyr Thr
100 105 110Leu Val Lys Thr Leu
Cys Gly Leu His Asp Leu Ile Pro Phe Asn 115 120
1252355PRTArtificial SequenceSynthetic polypeptide 23Met Asn
Ile Ile Asp Ser Ser Gly Lys Val Val Lys Phe Asp Met Pro1 5
10 15Phe Arg Val Trp Arg Lys Phe Ala
Ser Arg Arg Ser Ile Gly Tyr Gln 20 25
30Ser Trp Glu Glu Gly Lys Trp Val Lys Leu Asp Thr Lys Ala Thr
Asn 35 40 45Lys Leu Thr Ala Glu
Phe Met 50 5524121PRTArtificial SequenceSynthetic
polypeptide 24Met Lys Ala Leu Leu Val Leu Ala Phe Leu Pro Leu Thr His Cys
Cys1 5 10 15Arg Phe Thr
Phe Ser Lys Leu Trp Thr Ile Arg Asp Cys Tyr Pro Phe 20
25 30Val Pro Val Arg Glu Glu Pro Trp Leu Phe
Thr Ile Leu Ile Val Ala 35 40
45Ala Leu Ile Ala Phe Phe Ala Ala Ile Tyr Leu Arg Asn Ile Leu Pro 50
55 60Phe Ser Trp Asn Thr Asp Asp Leu Leu
Asp Tyr Pro Ile Leu Pro Gln65 70 75
80Pro Asn Val Ile Pro Leu Gln Asn Leu Leu Pro Asn Leu Pro
Asp Leu 85 90 95Leu Asp
Gln Leu Pro Pro Asn Pro Asp Pro Pro Arg Ser Pro Ser Thr 100
105 110Cys Ser Tyr Phe Arg Phe Thr Asn Glu
115 1202592PRTArtificial SequenceSynthetic
polypeptide 25Met Thr Leu Ala Leu Leu Ile Cys Thr Leu Thr Val Pro Val Thr
Leu1 5 10 15Ala Thr Val
Ser Phe Ala Thr Ala Thr His Leu Glu Pro Glu Cys Leu 20
25 30Pro Pro Phe Gln Val Tyr Leu Val Phe Ser
Phe Leu Cys Cys Thr Cys 35 40
45Ile Ala Ser Leu Ile Thr Leu Leu Leu Val Phe Phe Gln Phe Val Asp 50
55 60Tyr Phe Leu Val Arg Leu Arg Tyr Arg
His His Ala Pro Gln Phe Gln65 70 75
80Asn Pro Asn Val Ala Arg Leu Leu Ala Leu Gln Pro
85 9026155PRTArtificial SequenceSynthetic
polypeptide 26Met Lys Phe Leu Leu Phe Thr Ile Leu Phe Ser Leu Cys Gly Ser
Ser1 5 10 15His Ser Val
Phe Tyr Pro Pro Pro Asn Cys Tyr Val Thr Ser Arg Trp 20
25 30Asp Pro Asn Cys His Ile Gln Ile Leu Cys
Pro Asp Asn Ser Thr Ile 35 40
45Tyr Tyr Ser Asn Thr Ser Val Val Gly Ser Leu Thr Leu Asn Pro Glu 50
55 60Asp Asn Pro Pro Asp His Tyr Leu Ile
Asn His Thr Leu Ser Asn Gly65 70 75
80Lys Thr Ala Leu Tyr Asn Phe Thr Phe Pro Met Ala Thr Leu
Cys Thr 85 90 95Ile Thr
Glu Ala Thr Asp Ser Gly Tyr Asp Phe Thr Val Leu Phe Leu 100
105 110Leu Leu Met Val Val Ala Leu Ile Leu
Leu Leu Ala Ala Leu Ala Cys 115 120
125Leu Phe Tyr His Tyr Cys Arg Trp Trp Arg Lys Gly Ser Tyr Thr Leu
130 135 140Pro His Asp Gln Arg Ser Ile
His Leu Glu Ile145 150
15527342PRTArtificial SequenceSynthetic Polypeptide\ 27Met Gln Thr Ser
Ala Ala Ile Cys Val Leu Ala Leu Ile Ser Phe Val1 5
10 15Ser Cys Val Gln Pro Ala Ser Gly Gln Ile
Asp Val Cys Gln Ala Ala 20 25
30Asn Val Thr Val Thr Asp Leu Ser Lys Pro Thr Ile Thr Val Lys Cys
35 40 45Gly Phe Tyr Asn Lys Pro Val Ser
Thr Val Phe Trp Tyr Phe Asn Asn 50 55
60Thr Leu Phe Ser Ser Phe Asn Pro Phe Ser Leu Leu Ile Ser Asn Ile65
70 75 80Lys Gln Pro Phe Asn
Tyr Tyr Thr Thr Gly Asn Ser Leu Gln Leu Phe 85
90 95Ala Pro Tyr Ser Ser Gly Arg Tyr His Cys Glu
Val Leu Lys Cys Thr 100 105
110Gln His Phe Phe Ile Gly Ile Lys Pro Ala Thr Pro Ile Thr Thr Ala
115 120 125Ala Thr Thr Thr Thr Pro Asn
Thr Thr Ala Val Thr Thr Pro Pro Pro 130 135
140Ala Thr Ala Ser Ser Thr Thr Thr Pro Pro Ala Ala Ala Thr Thr
Ser145 150 155 160Ser Pro
Ser Ala Pro Lys Arg Ser Ile Arg Ser Phe Ser His Ser Phe
165 170 175Leu Ser Ile Asn Val Ser Asp
Pro Thr Gln Val Leu Gln Cys Pro Cys 180 185
190Ser Gly Asn Tyr Thr Phe Trp Gly Val Asn Gly Thr Asp Trp
Ala Phe 195 200 205Val Gln Asn Ile
Thr Phe Val Thr Phe Ile Gln Asn Gln Thr Ile Asn 210
215 220Phe Asn His Lys Phe Leu Asn Thr Ser Leu Asn Leu
Arg Leu Pro Val225 230 235
240Val Pro Gly Asn Tyr Ser Cys Asp Thr Gln Ser Arg Gln Cys Gln His
245 250 255Val Phe Thr Val Thr
Val Ile Tyr Pro Thr Pro Thr Thr Pro Ala Pro 260
265 270Pro Thr Thr Ala Thr Glu Thr Asn Thr His Gln Ala
Phe Phe Ala Pro 275 280 285Ser Glu
Ala Pro Glu Thr Ala Val Ala Ser Thr Pro Trp Trp Leu Phe 290
295 300Val Val Val Gly Ile Val Val Val Ile Ile Ala
Gly Ala Val Thr Ala305 310 315
320Phe Phe Ile Tyr Lys Lys His Pro Glu Val Val Val Phe Phe His Arg
325 330 335Val Pro Thr Ser
Val Tyr 34028109PRTArtificial SequenceSynthetic polypeptide
28Met Ser Asn Glu Phe Glu Ser Leu Val Asp Gln Ala Arg Ile Arg His1
5 10 15Leu Asp His Cys Arg Arg
His Arg Cys Phe Val Arg Glu His Leu Gln 20 25
30Thr Val Tyr Phe Glu His Pro Glu Ser His Pro Asp Gly
Pro Cys His 35 40 45Gly Ile Tyr
Val Ile Val Asp Gly Ser Cys Asp Thr His Leu Val Arg 50
55 60Tyr Tyr Ser Gln Arg Pro Leu Leu Val Glu Arg Gln
Thr Gly Val Thr65 70 75
80Lys Ile Thr Leu Thr Cys Ile Cys Ser Gln Pro Gly Leu His Ala Asp
85 90 95Leu Cys Cys His Leu Cys
Ala Arg Phe Asn Gln Leu Arg 100
10529233PRTArtificial SequenceSynthetic polypeptide 29Met Ser Lys Glu Ile
Pro Thr Pro Tyr Met Trp Ser Tyr Gln Pro Gln1 5
10 15Met Gly Leu Ala Ala Gly Ala Ala Gln Asp Tyr
Ser Thr Lys Met Asn 20 25
30Trp Leu Ser Ala Gly Pro His Met Ile Ala Gln Val Asn Gly Ile Arg
35 40 45Ala His Arg Asn Gln Leu Leu Leu
Glu Gln Ala Ala Leu Thr Thr Thr 50 55
60Pro Arg Asn Gln Leu Asn Pro Pro Ser Trp Pro Ala Ser Leu Val Tyr65
70 75 80Gln Glu Thr Pro Ala
Pro Thr Thr Val Leu Leu Pro Arg Asp Ala Gln 85
90 95Ala Glu Val Leu Met Thr Asn Ser Gly Ala Gln
Leu Ala Gly Gly Ala 100 105
110Cys Arg Tyr Arg Ser Lys Gly Pro Thr Gly Leu Ser Ala Pro Leu Gly
115 120 125Ile Lys Arg Val Leu Ile Arg
Gly Arg Gly Thr Gln Leu Asn Asp Glu 130 135
140Thr Val Ser Ser Ser Leu Gly Leu Arg Pro Asp Gly Val Phe Gln
Leu145 150 155 160Ala Gly
Ser Gly Arg Ser Ser Phe Thr Pro Arg Gln Ala Tyr Leu Thr
165 170 175Leu Gln Ser Ser Ser Ser Gln
Pro Arg Ser Gly Gly Ile Gly Thr Leu 180 185
190Gln Phe Val Glu Glu Phe Thr Pro Ser Val Tyr Phe Asn Pro
Phe Ser 195 200 205Gly Ala Pro Gly
Leu Tyr Pro Asp Glu Phe Ile Pro Asn Phe Asp Ala 210
215 220Val Thr Asp Ser Val Asp Gly Tyr Asp225
23030254PRTArtificial SequenceSynthetic polypeptide 30Met Pro Pro Lys
Lys Arg Ser Ala Ala Leu Pro Leu Ser Lys Ala Val1 5
10 15Thr Ala Lys Arg Pro Lys Gln Arg Lys Ala
Gln Glu Thr Glu Glu Pro 20 25
30Trp Ser Glu Glu Glu Asp Trp Glu Ser Gln Gly Glu Glu Asp Met Glu
35 40 45Glu Glu Trp Asp Ser Leu Ala Ser
Asp Glu Gly Glu Ala Glu Ala Glu 50 55
60Thr Glu Glu Ala Ser Val Ala Lys Pro Ser Leu Ala Lys Arg Val Ser65
70 75 80Asn Val Thr Thr Thr
Ser Asp Gln Arg Thr Val Ser Arg Arg Trp Asp 85
90 95Ser Thr Asn Ala Ala Pro Ala Gly Lys Thr Leu
Ser Leu Ala Lys Pro 100 105
110Arg Gln Gly Tyr Arg Ser Trp Arg Ala His Lys Asn Ala Ile Ile Asn
115 120 125Cys Leu Glu Asn Cys Gly Gly
Asn Ile Ser Phe Thr Arg Arg Phe Met 130 135
140Leu Phe Arg Asn Gly Ile Ala Ile Pro Arg Asn Val Leu His Tyr
Tyr145 150 155 160Arg His
Ser Tyr Ser Pro Ser Lys Thr Arg Leu Pro Lys Gln Asn Lys
165 170 175Lys Gln Val Lys Glu Pro Pro
Ser Thr Lys Glu Leu Arg Asn Arg Ile 180 185
190Phe Pro Thr Leu Tyr Ala Ile Phe Gln Gln Ser Arg Gly Gln
Glu Pro 195 200 205Glu Leu Lys Ile
Lys Asn Arg Ser Leu Arg Ser Leu Thr Arg Ser Cys 210
215 220Leu Tyr His Lys Asn Glu Glu Gln Leu Gln Arg Thr
Leu Asp Asp Ala225 230 235
240Glu Ala Leu Phe Asn Lys Tyr Cys Ala Ala Thr Leu Lys Glu
245 25031180PRTArtificial SequenceSynthetic polypeptide
31Met Pro Pro Lys Lys Arg Ser Ala Ala Leu Pro Leu Ser Lys Ala Val1
5 10 15Thr Ala Lys Arg Pro Lys
Gln Arg Lys Ala Gln Glu Thr Glu Glu Pro 20 25
30Trp Ser Glu Glu Glu Asp Trp Glu Ser Gln Gly Glu Glu
Asp Met Glu 35 40 45Glu Glu Trp
Asp Ser Leu Ala Ser Asp Glu Gly Glu Ala Glu Ala Glu 50
55 60Thr Glu Glu Ala Ser Val Ala Lys Pro Ser Leu Ala
Lys Arg Val Ser65 70 75
80Asn Val Thr Thr Thr Ser Asp Gln Arg Thr Val Ser Arg Arg Trp Asp
85 90 95Ser Thr Asn Ala Ala Pro
Ala Gly Lys Thr Leu Ser Leu Ala Lys Pro 100
105 110Arg Gln Gly Tyr Arg Ser Trp Arg Ala His Lys Asn
Ala Ile Ile Asn 115 120 125Cys Leu
Glu Asn Cys Gly Gly Asn Ile Ser Phe Thr Arg Arg Phe Met 130
135 140Leu Phe Arg Asn Gly Ile Ala Ile Pro Arg Asn
Val Leu His Tyr Tyr145 150 155
160Arg His Ser Tyr Ser Pro Ser Lys Thr Val Pro Leu Gly Ser Gly Gly
165 170 175Arg Gly Gly His
18032780PRTArtificial SequenceSynthetic polypeptide 32Met Glu
Leu Glu Pro Ala Ala Glu Ser Asn Asn Leu Thr Ser Pro His1 5
10 15Phe Tyr Glu Asn Lys Asp Ala Leu
Thr Glu Ala Thr Gly Ser Ala Val 20 25
30Glu Gln Asp Val Gly Tyr Ala Ser Pro Pro Glu Thr Ala Glu Glu
Glu 35 40 45Lys Asp Asp Lys Asn
Leu Ser Ser Pro Gln Lys Asp Lys Gln Gln Asp 50 55
60Asp Lys Thr Gln Glu Asn Glu Glu Asp Val Ser Phe His Asp
Asp Tyr65 70 75 80Leu
Gly Lys Gly Glu Asp Val Leu Leu Lys His Ile Arg Arg Gln Ser
85 90 95Ala Ile Val Glu Asn Ala Ile
Ser Glu Lys Thr Glu Ile Pro Val Ser 100 105
110Val Tyr Asp Leu Ser Leu Ala Tyr Glu Gln Ser Leu Phe Ser
Pro Arg 115 120 125Val Pro Pro Lys
Arg Gln Pro Asn Gly Thr Cys Glu Pro Asn Pro Arg 130
135 140Leu Asn Phe Tyr Pro Ala Phe Ala Val Pro Glu Val
Leu Ala Thr Tyr145 150 155
160His Ile Phe Phe Lys Asn His Lys Ile Pro Val Ser Cys Arg Ala Asn
165 170 175Arg Ser Glu Ala Asp
Ala Gln Leu Leu Leu Gly Pro Gly Ala Arg Ile 180
185 190Pro Asp Phe Ala Ser Leu Glu Glu Val Pro Lys Ile
Phe Glu Gly Leu 195 200 205Gly Asp
Glu Lys Arg Ala Ala Asn Ala Leu Gln Glu Asn Thr Glu Ser 210
215 220Phe Ser Ala Leu Val Glu Leu Ala Asn Asp Asn
Ala Arg Leu Ala Val225 230 235
240Leu Lys Arg Ser Val Glu Val Thr His Phe Ala Tyr Pro Ala Val Asn
245 250 255Leu Pro Pro Lys
Val Met Asn Thr Val Met Asp Cys Leu Leu Val Lys 260
265 270Arg Ala Lys Pro Leu Gly Glu Gly Glu Gln Glu
Glu Glu Asp Ser Asp 275 280 285Glu
Gly Lys Pro Ala Val Thr Asp Glu Glu Leu Ser Arg Trp Leu Arg 290
295 300Thr Thr Asp Pro Ala Glu Leu Glu Asn Arg
Arg Lys Leu Met Thr Ala305 310 315
320Val Ile Leu Val Thr Ala Glu Leu Glu Cys Leu Ser Arg Phe Phe
Thr 325 330 335Asp Thr Glu
Thr Ile Arg Lys Val Glu Glu Thr Leu His Tyr Thr Phe 340
345 350Arg His Gly Tyr Val Lys Gln Ala Cys Lys
Ile Ser Asn Val Glu Leu 355 360
365Ser Asn Leu Val Ser Tyr Leu Gly Ile Leu His Glu Asn Arg Leu Gly 370
375 380Gln Asn Val Leu His Ala Thr Leu
Lys Gly Glu Ala Arg Arg Asp Tyr385 390
395 400Ile Arg Asp Cys Val Tyr Leu Phe Leu Cys Phe Thr
Trp Gln Ser Ala 405 410
415Met Gly Val Trp Gln Gln Cys Leu Glu Asp Asp Asn Leu Arg Glu Leu
420 425 430Gln Lys Ile Leu Asn Arg
Glu Arg Arg Asp Leu Trp Thr Gly Phe Asp 435 440
445Glu Arg Thr Val Ala Lys Asp Leu Ala Asn Ile Ile Phe Pro
Ser Arg 450 455 460Leu Val Arg Thr Leu
Gln Asn Gly Leu Pro Asp Phe Met Ser Gln Ser465 470
475 480Met Ile Gln Asn Phe Arg Ser Phe Ile Leu
Glu Arg Ser Gly Ile Leu 485 490
495Pro Ser Met Ser Cys Ala Leu Pro Ser Asp Phe Ile Pro Leu Thr Phe
500 505 510Arg Glu Cys Pro Pro
Pro Leu Trp Ser His Cys Tyr Leu Phe Gln Leu 515
520 525Ala Asn Phe Phe Ala Phe His Ser Asp Val Val Ala
Asp Val Thr Gly 530 535 540Glu Gly Leu
Met Glu Cys His Cys Arg Cys Asn Leu Cys Thr Pro His545
550 555 560Arg Ser Leu Val Cys Asn Thr
Ala Leu Leu Asn Glu Thr Gln Val Ile 565
570 575Gly Thr Phe Glu Ile Gln Gly Pro Ser Glu Ser Asn
Lys Gly Ala Ala 580 585 590Gly
Leu Lys Leu Thr Pro Gly Leu Trp Thr Ser Ala Tyr Leu Arg Lys 595
600 605Phe Val Pro Val Asp Tyr His Ala His
Glu Ile Arg Phe Tyr Glu Asp 610 615
620Gln Ser Gly Pro Pro Lys Ala Glu Leu Ser Ala Cys Val Ile Thr Gln625
630 635 640Ser Ser Ile Val
Ala Gln Leu Gln Ala Ile Asn Glu Ala Arg Arg Asn 645
650 655Phe Leu Leu Lys Lys Gly Lys Gly Val Tyr
Leu Asp Pro Gln Thr Gly 660 665
670Glu Glu Leu Asn Thr Thr Pro Ser Pro Val Ala Gly Val Ser His Asn
675 680 685Ala Thr Lys Glu Glu Val Arg
Arg Pro Pro Ala Leu Gln Ser Ser His 690 695
700Ser Lys Ala Thr Gln Thr Glu Glu Ser Pro Gly Asp Arg Gly Thr
Met705 710 715 720Glu Arg
Gly Gly Gly Leu Gly Glu Ser Gly Arg Gly Arg His Gly Arg
725 730 735Gly Met Gly Gln Pro Ser Gln
Arg Arg Gly Arg Gly Arg Gly Arg Asp 740 745
750Arg Gly Ser Ile Arg Arg Lys Thr Leu Thr Gly Glu Thr Ser
Phe Lys 755 760 765Arg Tyr Tyr Asp
Leu Arg Ser Ala His Ser Gln Ser 770 775
78033457PRTArtificial SequenceSynthetic polypeptide 33Met Ala Ser Asn
Gln Asp Arg Arg Glu Val Thr Pro Glu Lys Val Pro1 5
10 15Ala Val Pro Pro Lys Lys Lys Ala Arg Lys
Ser Leu Pro Leu Pro Pro 20 25
30Ser Pro Glu Val Val Ala Asp Ser Asp Glu Glu Val Gly Glu Leu Leu
35 40 45Glu Val Gly Phe Ser Tyr Pro Pro
Val Lys Ile Val Arg Lys Ala Asp 50 55
60Gly Ser Lys Ala Phe Glu Lys Phe Asp Glu Asn His Pro Ile Met Ser65
70 75 80Ala Ala Arg Gln Gln
Lys Glu Gly Thr Ser Ser Thr Val Val Asn Pro 85
90 95Ala Ser Asn Pro Leu Val Ser Ala Trp Glu Lys
Gly Met Glu Phe Met 100 105
110Val Met Leu Met Glu Arg Tyr Lys Val Asp Lys Glu Leu Arg Ser Ser
115 120 125Phe Lys Phe Leu Pro Glu Gln
Gly Glu Val Tyr Arg Lys Ile Cys Gln 130 135
140Ala Trp Met Asn Glu Glu Tyr Lys His Asn Thr Leu Thr Phe Thr
Ser145 150 155 160His Lys
Ser Phe Ile Ser Leu Met Gly Arg Phe Leu Met Ala Tyr Val
165 170 175Gln Val Tyr Ala Gly Val Asp
Ser Lys Leu Trp Glu Pro Thr Gly Cys 180 185
190Val Ala Trp Glu His Gln Cys Thr Asp Val Glu Gly Glu Leu
Lys Cys 195 200 205Leu His Gly Leu
Thr Met Ile Val Lys Glu Gln Ile Ile Glu Met Asp 210
215 220Val Thr Ser Glu Asn Gly Gln Arg Ala Leu Lys Glu
Thr Pro Ala Lys225 230 235
240Ala Lys Ile Val Gln Asn Arg Trp Gly Arg Ser Val Val Gln Val Arg
245 250 255Asn Glu Asp Ala Arg
Cys Cys Met Phe Asp Ala Gly Cys Ser Pro Asn 260
265 270Asn Phe Ser Asn Lys Ser Cys Gly Met Phe Tyr Ser
Glu Gly Thr Lys 275 280 285Ala Gln
Ile Ala Phe Arg Gln Ile Ala Ala Phe Met Gln Ala Cys Tyr 290
295 300Pro His Met Val Lys Gly Ser Lys His Leu Leu
Met Pro Ile Arg Cys305 310 315
320Asn Cys Phe Thr Arg Pro Glu Met Ser Arg Gly Gly Arg Gln Thr Cys
325 330 335Lys Ile Thr Pro
Phe Ala Leu Asn Val Glu Asn Ile His Leu Glu Asp 340
345 350Leu Val Asp Phe Gly Tyr His Asp Arg Ala Met
Leu Ala Ser Val Asn 355 360 365Asn
Pro Ser Val Leu Val Phe Gln Cys Ala Asn Ala Leu His Arg Asn 370
375 380Ser Lys Ala Asn Asn Gln Ala Asn Cys Asp
Phe Lys Ile Ser Ala Pro385 390 395
400Asp Val Ile Gly Ala Leu Gln Leu Val Arg Gln Phe Trp Gln Asp
His 405 410 415Leu Pro Asp
Thr Val Leu Pro Lys Met Val Val Pro Glu Phe Lys Trp 420
425 430His Pro Lys Tyr Gln Tyr Arg Asn Leu Thr
Leu Pro Ala Ala His Val 435 440
445Asp Phe Glu Met Asn Pro Phe Glu Phe 450
45534206PRTArtificial SequenceSynthetic polypeptide 34Met Gly Ser Ser Glu
Glu Glu Leu Lys Ala Ile Ile Arg Asp Leu Arg1 5
10 15Cys Ala Pro Tyr Phe Leu Gly Thr Phe Asp Lys
Arg Phe Pro Gly Phe 20 25
30Val Ser Pro His Lys Leu Ala Cys Ala Ile Val Asn Thr Ala Gly Arg
35 40 45Glu Thr Gly Gly Val His Trp Leu
Ala Phe Gly Trp Asn Pro Lys Asn 50 55
60Arg Thr Cys Tyr Leu Phe Asp Pro Phe Gly Phe Ser Asp Glu Lys Leu65
70 75 80Lys Gln Ile Tyr Gln
Phe Glu Tyr Glu Asn Leu Leu Lys Arg Ser Ala 85
90 95Ile Ala Ser Thr Pro Asp Arg Cys Val Thr Leu
Val Lys Ser Thr Gln 100 105
110Thr Val Gln Gly Pro Asn Ser Ala Ala Cys Gly Leu Phe Ala Cys Met
115 120 125Phe Leu His Ala Phe Val Asn
Trp Pro Asn Ser Pro Met Glu Asn Asn 130 135
140Pro Thr Met Asp Leu Ile Val Gly Val Pro Asn Tyr Met Leu Lys
Ser145 150 155 160Pro Gln
Val Gln Gly Thr Leu Phe Lys Asn Gln Gln Ala Leu Tyr Arg
165 170 175Phe Leu Ala Thr His Ser Pro
Tyr Phe Arg His His Gln Gln Gln Ile 180 185
190Glu Lys Ala Thr Ala Phe Asn Lys Gln Thr Glu Ser Lys Asn
195 200 20535937PRTArtificial
SequenceSynthetic polypeptide 35Met Ala Thr Pro Ser Met Met Pro Gln Trp
Ser Tyr Met His Ile Ala1 5 10
15Gly Gln Asp Ala Ser Glu Tyr Leu Ser Pro Gly Leu Val Gln Phe Ala
20 25 30Arg Ala Thr Asp Thr Tyr
Phe Thr Leu Gly Asn Lys Phe Arg Asn Pro 35 40
45Thr Val Ala Pro Thr His Asp Val Thr Thr Asp Arg Ser Gln
Arg Leu 50 55 60Thr Leu Arg Phe Val
Pro Val Asp Arg Glu Asp Thr Ala Tyr Ala Tyr65 70
75 80Lys Ala Arg Phe Thr Leu Ser Val Gly Asp
Asn Arg Val Leu Asp Met 85 90
95Ala Ser Thr Tyr Phe Asp Ile Arg Gly Val Ile Asp Arg Gly Pro Ser
100 105 110Phe Lys Pro Tyr Ser
Gly Thr Ala Tyr Asn Ala Leu Ala Pro Lys Gly 115
120 125Ala Pro Asn Asn Ser Gln Trp His Thr Val Asn Glu
Asp Asn Gln Asn 130 135 140Phe Leu Met
His Thr Tyr Ala Gln Ala Pro Phe Glu Ser Glu Phe Val145
150 155 160Ala Asn Asn Gly Asn Ile Gly
Ile Gln Val Gly Val Ser Asp Thr Asn 165
170 175Thr Pro Ile Leu Ala Asp Pro Thr Tyr Gln Pro Glu
Pro Gln Asp Gly 180 185 190Glu
Pro Gln Trp Gln Ser Leu Lys Ala Gln Glu Lys Leu Glu His Ala 195
200 205Gly Arg Ala Leu Lys Tyr Thr Thr Pro
Met Lys Pro Cys Tyr Gly Ser 210 215
220Tyr Ala Arg Pro Thr Asn Ala Gln Gly Gly Gln Gly Ile Ile Asp Glu225
230 235 240Gln Thr Gly Glu
Thr Asp Ala Thr Glu Ile Thr Gln Asn Tyr Phe Ala 245
250 255Leu Ser Thr Ala Thr Thr Asp Phe Thr Pro
Lys Val Val Leu Tyr Thr 260 265
270Glu Asp Val Tyr Leu Gln Thr Pro Asp Thr His Leu Val Tyr Thr Pro
275 280 285Ser Ala Thr Glu Gly Ser Thr
Gln Asp Met Leu Gly Gln Gln Ala Ala 290 295
300Pro Asn Arg Pro Asn Tyr Ile Gly Phe Arg Asp Asn Phe Ile Gly
Leu305 310 315 320Met Tyr
Tyr Asn Ser Thr Gly Asn Met Gly Val Leu Ala Gly Gln Ala
325 330 335Ser Gln Leu Asn Ala Val Val
Asp Leu Gln Asp Arg Asn Thr Glu Leu 340 345
350Ser Tyr Gln Leu Met Leu Asp Ala Leu Ser Asp Arg Thr Arg
Tyr Phe 355 360 365Ser Met Trp Asn
Gln Ala Val Asp Ser Tyr Asp Pro Asp Val Arg Ile 370
375 380Ile Glu Asn His Gly Val Glu Asp Glu Leu Pro Thr
Tyr Cys Phe Pro385 390 395
400Leu Ser Gly Val Gly Ile Thr Gln Glu Tyr Gln Gly Val Glu Pro Thr
405 410 415Asn Pro Ala Ala Ala
Asp Ile Thr Trp Lys Glu Asp Ala Thr Val Phe 420
425 430Asp Pro Asn Tyr Ile Ala Thr Gly Asn Ile Asn Ala
Tyr Glu Ile Asn 435 440 445Leu Gln
Ala Ser Leu Trp Arg Ser Phe Leu Tyr Ser Asn Val Ala Leu 450
455 460Tyr Leu Pro Asp Lys Tyr Lys Tyr Thr Pro Ala
Asn Val Thr Leu Pro465 470 475
480Thr Asn Thr Asn Thr Tyr Lys Tyr Met Asn Gly Arg Val Thr Ser Pro
485 490 495Ser Leu Val Asp
Ile Phe Val Asn Val Gly Ala Arg Trp Ser Pro Asp 500
505 510Pro Met Asp Asn Val Asn Pro Phe Asn His His
Arg Asn Ala Gly Leu 515 520 525Arg
Tyr Arg Ser Gln Leu Leu Gly Asn Gly Arg Ile Val Pro Phe His 530
535 540Ile Gln Val Pro Gln Lys Phe Phe Ala Ile
Lys Asn Leu Leu Leu Leu545 550 555
560Pro Gly Ser Tyr Thr Tyr Glu Trp Ser Phe Arg Lys Asp Val Asn
Met 565 570 575Ile Leu Gln
Ser Thr Leu Gly Asn Asp Leu Arg Thr Asp Gly Ala Ala 580
585 590Ile Arg Ile Glu Ser Val Asn Leu Tyr Ala
Asn Phe Phe Pro Met Ala 595 600
605His Asn Thr Ala Ser Thr Leu Glu Ala Met Leu Arg Asn Asp Thr Asn 610
615 620Asp Gln Ser Phe Asn Asp Tyr Leu
Ser Ala Ala Asn Met Leu Tyr Pro625 630
635 640Ile Pro Ala Asn Ala Thr Asn Val Pro Ile Ser Ile
Pro Ser Arg Asn 645 650
655Trp Ala Ala Phe Arg Gly Trp Ser Phe Thr Arg Leu Lys Ala Lys Glu
660 665 670Thr Pro Ala Leu Gly Ser
Gly Phe Asp Pro Tyr Phe Val Tyr Ser Gly 675 680
685Ser Ile Pro Tyr Leu Asp Gly Thr Phe Tyr Leu Asn His Thr
Phe Lys 690 695 700Arg Val Ser Ile Met
Phe Asp Ser Ser Val Ser Trp Pro Gly Asn Asp705 710
715 720Arg Leu Leu Thr Pro Asn Glu Phe Glu Val
Lys Arg Val Val Asp Gly 725 730
735Glu Gly Tyr Thr Val Ala Gln Ser Asn Met Thr Lys Asp Trp Phe Leu
740 745 750Ile Gln Met Leu Ser
His Tyr Asn Ile Gly Tyr Gln Gly Phe Tyr Ile 755
760 765Pro Glu Gly Tyr Lys Asp Arg Met Tyr Ser Phe Phe
Arg Asn Phe Gln 770 775 780Pro Met Thr
Arg Gln Ala Val Asp Pro Val Asn Tyr Thr Asn Tyr Lys785
790 795 800Glu Ile Thr Val Ala His Gln
His Asn Asn Ser Gly Phe Val Gly Phe 805
810 815Met Gly Pro Thr Met Arg Glu Gly His Pro Tyr Pro
Ala Asn Tyr Pro 820 825 830Tyr
Pro Leu Ile Gly Asp Ser Ala Val Pro Thr Val Thr Gln Lys Lys 835
840 845Phe Leu Cys Asp Arg Thr Met Trp Arg
Ile Pro Phe Ser Ser Asn Phe 850 855
860Met Ser Met Gly Ala Leu Thr Asp Leu Gly Gln Asn Met Leu Tyr Ala865
870 875 880Asn Ser Ala His
Ala Leu Asp Met Thr Phe Glu Val Asp Pro Met Asp 885
890 895Glu Pro Thr Leu Leu Tyr Val Leu Phe Glu
Val Phe Asp Val Val Arg 900 905
910Val His Gln Pro His Arg Gly Ile Ile Glu Ala Val Tyr Leu Arg Thr
915 920 925Pro Phe Ser Ala Gly Asn Ala
Thr Thr 930 93536247PRTArtificial SequenceSynthetic
polypeptide 36Met Glu Asp Val Asn Phe Ser Ser Leu Ala Pro Arg His Gly Thr
Arg1 5 10 15Pro Tyr Leu
Gly Thr Trp Asn Asp Ile Gly Thr Ser Gln Leu Asn Gly 20
25 30Gly Ala Phe Asn Trp Ser Ser Ile Trp Ser
Gly Leu Lys Asn Phe Gly 35 40
45Ser Thr Ile Lys Ser Tyr Gly Asn Arg Ala Trp Asn Ser Ser Thr Gly 50
55 60Gln Leu Leu Arg Asp Lys Leu Lys Asp
Gln Asn Phe Gln Gln Lys Val65 70 75
80Val Asp Gly Leu Ala Ala Gly Ile Asn Gly Val Val Asp Ile
Ala Asn 85 90 95Gln Ala
Val Gln Arg Glu Ile Asn Asn Arg Leu Asp Pro Arg Pro Val 100
105 110Glu Glu Glu Leu Pro Ala Leu Glu Arg
Gln Pro Gln Gly Glu Lys Arg 115 120
125Pro Arg Pro Asp Leu Glu Glu Thr Leu Val Thr Glu Glu Pro Pro Ser
130 135 140Tyr Glu Glu Ala Val Lys Gly
Ala Pro Ser Val Ala Leu Lys Pro Val145 150
155 160Thr Tyr Pro Leu Thr Lys Pro Ile Met Ser Met Ala
Thr Pro Val Gly 165 170
175Asp Ala Pro Met Val Val Asp Leu Pro Pro Pro Pro Ala Gly Met Thr
180 185 190Thr Pro Thr Val Pro Val
Pro Ile Ala Pro Pro Val Ser Arg Pro Ala 195 200
205Ile Arg Pro Val Ala Val Ala Thr Pro Arg Tyr Thr Arg Thr
Asn Asn 210 215 220Trp Gln Asn Thr Leu
Asn Ser Ile Val Gly Leu Gly Val Lys Thr Leu225 230
235 240Lys Arg Arg Arg Cys Tyr Tyr
24537340PRTArtificial SequenceSynthetic polypeptide 37Met Thr Lys Arg
Lys Phe Lys Glu Glu Leu Leu Gln Ala Ile Ala Pro1 5
10 15Glu Ile Tyr Ala Pro Leu Thr Asp Pro Asp
Val Lys Pro Asp Val Lys 20 25
30Pro Arg Arg Leu Lys Arg Val Lys Lys Gln Glu Thr Lys Lys Glu Glu
35 40 45Ala Leu Asp Thr Glu Gly Val Glu
Phe Val Arg Ser Phe Ala Pro Arg 50 55
60Arg Arg Val Gln Trp Lys Gly Arg Arg Val Arg Arg Leu Leu Arg Pro65
70 75 80Gly Thr Ala Val Val
Phe Thr Pro Gly Glu Arg Ser Ser Arg Thr Tyr 85
90 95Lys Arg Ser Tyr Asp Glu Val Tyr Ala Asp Glu
Asp Ile Leu Glu Gln 100 105
110Ala Leu Glu Gln Ser Gly Glu Phe Ala Tyr Gly Lys Arg Ala Arg Asn
115 120 125Glu Val Ala Leu Pro Leu Asp
Glu Ser Asn Pro Thr Pro Ser Leu Lys 130 135
140Pro Val Thr Leu Gln Gln Val Leu Pro Val Gln Ser Thr Gly Glu
Ser145 150 155 160Lys Arg
Gly Ile Lys Arg Glu Ala Val Glu Leu Gln Pro Thr Met Gln
165 170 175Leu Met Val Pro Lys Arg Gln
Lys Leu Glu Asp Val Leu Asp Leu Met 180 185
190Thr Val Asp Pro Ser Val Gln Pro Asp Val Lys Ile Arg Pro
Ile Lys 195 200 205Glu Val Ala Pro
Gly Leu Gly Val Gln Thr Val Asp Ile Gln Ile Pro 210
215 220Val Glu Ser Met Asp Val Glu Lys Pro Lys Pro Thr
Ala Val Asp Met225 230 235
240Ala Val Gln Thr Asp Pro Trp Ala Gly Ala Pro Val Arg Ala Ala Ser
245 250 255Ala Ile Arg Asn Arg
Arg Arg Tyr Gly Pro Ala Ser Ser Leu Met Pro 260
265 270Asp Tyr Ala Leu His Pro Ser Ile Ile Pro Thr Pro
Gly Tyr Arg Gly 275 280 285Gln Val
Phe Arg Arg Arg Tyr Ser Ala Pro Ala Arg Arg Ser Thr Arg 290
295 300Arg Arg Arg Arg Arg Arg Thr Thr Leu Pro Val
Arg Val Arg Arg Val305 310 315
320Thr Thr Arg Arg Gly Arg Thr Leu Thr Leu Pro Thr Val Arg Tyr His
325 330 335Pro Thr Ile Val
3403875PRTArtificial SequenceSynthetic polypeptide 38Met Ala Leu
Thr Cys Arg Leu Arg Ile Pro Val Pro Gly Tyr Arg Gly1 5
10 15Arg Arg Arg His Gly Lys Gly Phe Arg
Gly Ser Gly Leu Thr Arg His 20 25
30Arg Arg Arg Arg Ala Val Arg Gly Arg Met Lys Gly Gly Ile Leu Pro
35 40 45Ala Leu Ile Pro Ile Ile Ala
Ala Ala Ile Gly Ala Ile Pro Gly Ile 50 55
60Ala Ser Val Ala Val Gln Ala Ser Gln Arg Gln65 70
7539190PRTArtificial SequenceSynthetic polypeptide 39Met
Ser Ile Leu Ile Ser Pro Ser Asn Asn Thr Gly Trp Gly Leu Gly1
5 10 15Val Asn Lys Met Tyr Gly Gly
Ala Lys His Arg Ser Thr Gln His Pro 20 25
30Val Arg Val Arg Gly His Tyr Arg Ala Pro Trp Gly Ala Tyr
Lys Arg 35 40 45Asn Arg Arg Val
Ala Glu Arg Thr Thr Val Asp Asp Val Ile Asp Ser 50 55
60Val Val Ala Asp Ala Arg Asn Tyr Val Pro Pro Ala Val
Pro Ala Ala65 70 75
80Ala Ala Ser Thr Val Asp Ala Val Ile Asp Ser Val Val Ala Asp Ala
85 90 95Arg Ala Tyr Ala Arg Gln
Lys Arg Arg Gln Arg Arg Ala Arg Arg Ser 100
105 110Leu Ala Arg Pro Thr Ala Ala Met Arg Ala Ala Arg
Asn Leu Leu Arg 115 120 125Arg Ala
Arg Arg Thr Ser Thr Arg Ala Met Ala Arg Gln Ile Arg Ala 130
135 140Gly Arg Thr Arg Arg Arg Ala Ala Gln Gln Ala
Ala Ala Ala Ile Ala145 150 155
160Ser Leu Ala Ala Pro Arg Arg Gly Asn Val Tyr Trp Val Arg Asp Ala
165 170 175Ser Gly Val Arg
Val Pro Val Arg Thr Arg Pro Ala Arg Val 180
185 19040485PRTArtificial SequenceSynthetic polypeptide
40Met Leu Arg Arg Gly Ile Pro Pro Val Ala Val Ala Glu Gly Pro Pro1
5 10 15Pro Ser Tyr Glu Ser Val
Met Ala Ala Ala Ala Leu Gln Gly Pro Leu 20 25
30Val Ala Pro Tyr Val Pro Pro Arg Tyr Leu Gly Pro Thr
Glu Gly Arg 35 40 45Asn Ser Ile
Arg Tyr Ser Glu Leu Ala Pro Leu Tyr Asp Thr Thr Arg 50
55 60Leu Tyr Leu Val Asp Asn Lys Ser Ala Asp Ile Ala
Ser Leu Asn Tyr65 70 75
80Gln Asn Asp His Ser Asn Phe Leu Thr Thr Val Val Gln Asn Asn Asp
85 90 95Tyr Thr Pro Ala Glu Ala
Gly Thr Gln Thr Ile Asn Phe Asp Asp Arg 100
105 110Ser Arg Trp Gly Gly Glu Met Lys Thr Ile Leu His
Thr Asn Met Pro 115 120 125Asn Ile
Asn Ala Tyr Met Phe Thr Asn Lys Phe Arg Ala Lys Leu Met 130
135 140Thr Ala His Glu Thr Asp Lys Asp Pro Val Tyr
Glu Trp Val Asp Leu145 150 155
160Val Leu Pro Glu Gly Asn Phe Ser Glu Thr Met Thr Ile Asp Leu Met
165 170 175Asn Asn Ala Ile
Val Asp His Tyr Leu Leu Val Gly Arg Gln Asn Gly 180
185 190Val Lys Glu Ser Glu Ile Gly Val Lys Phe Asp
Thr Arg Asn Phe Arg 195 200 205Leu
Gly Trp Asp Pro Glu Thr Gln Leu Val Met Pro Gly Val Tyr Thr 210
215 220Asn Glu Ala Phe His Pro Asp Ile Val Leu
Leu Pro Gly Cys Gly Val225 230 235
240Asp Phe Thr Asn Ser Arg Leu Asn Asn Leu Leu Gly Ile Arg Lys
Arg 245 250 255Gln Pro Phe
Gln Glu Gly Phe Gln Ile Leu Tyr Glu Asp Leu Val Gly 260
265 270Gly Asn Ile Pro Ala Leu Leu Asp Val Thr
Ala Tyr Glu Asn Ser Thr 275 280
285Pro Gly Gln Pro Pro Thr Ile Gln Pro Val Thr Glu Asp Ala Lys Asn 290
295 300Arg Ser Tyr Asn Val Leu Pro Gly
Thr Asn Asn Thr Ala Tyr Arg Ser305 310
315 320Trp Tyr Leu Ala Tyr Asn Tyr Gly Asp Asp Thr Gly
Ile Arg Ser Ser 325 330
335Thr Leu Leu Thr Ala Pro Asp Val Thr Cys Gly Ser Glu Gln Ile Tyr
340 345 350Trp Ser Met Pro Asp Met
Met Gln Asp Pro Val Thr Phe Arg Ser Ser 355 360
365Gln Gln Thr Ser Asn Leu Pro Val Val Gly Thr Glu Leu Leu
Pro Met 370 375 380Tyr Ala Lys Ser Phe
Tyr Asn Asp Gln Ala Val Tyr Ser Gln Leu Ile385 390
395 400Arg Gln Ser Thr Ala Leu Thr His Val Phe
Asn Arg Phe Pro Glu Asn 405 410
415Gln Ile Leu Val Arg Pro Pro Ala Pro Thr Ile Thr Thr Val Ser Glu
420 425 430Asn Val Pro Ala Leu
Thr Asp His Gly Thr Leu Pro Leu Gln Asn Ser 435
440 445Ile Arg Gly Val Gln Arg Val Thr Ile Thr Asp Ala
Arg Arg Arg Thr 450 455 460Cys Pro Tyr
Val Tyr Lys Ala Leu Gly Val Val Ala Pro Lys Val Leu465
470 475 480Ser Ser Arg Thr Phe
48541632PRTArtificial SequenceSynthetic polypeptide 41Met Ala Leu Ser
Val Gln Asp Cys Ala Arg Leu Thr Gly Gln Ser Val1 5
10 15Pro Thr Val Asp Phe Phe Leu Pro Leu Arg
Asn Ile Trp Asn Arg Val 20 25
30Gln Glu Phe Thr Arg Ala Ala Thr Thr Val Ala Gly Ile Ser Trp Met
35 40 45Ser Arg Tyr Leu Tyr Gly Tyr His
Arg Leu Met Leu Glu Asp Leu Ser 50 55
60Pro Asn Ala Pro Ala Thr Arg Gly Trp Pro Leu Phe Arg Leu Pro Pro65
70 75 80Pro His Leu Leu Val
Gly Tyr Gln Tyr Leu Val Arg Thr Cys Asn Asp 85
90 95Tyr Val Phe Glu Thr Arg Ala Tyr Ser Arg Leu
Lys Tyr Arg Glu Thr 100 105
110Leu Gln Pro Gly His Gln Thr Val Asn Trp Ser Val Met Ala Asn Cys
115 120 125Thr Tyr Thr Ile Asn Thr Gly
Ala Tyr His Arg Phe Val Asp Leu Asp 130 135
140Asp Phe Gln Asn Thr Leu Thr Gln Ile Gln Gln Ala Ile Leu Met
Glu145 150 155 160Arg Val
Val Ala Asp Leu Ala Leu Leu Glu Pro Phe Arg Gly Phe Gly
165 170 175Ala Thr Arg Met Asp Asp Arg
Glu Val Ser Val Glu Thr Leu Met Gln 180 185
190Asp Tyr Tyr Lys Asp Leu Arg Arg Cys Gln Gly Glu Ala Trp
Gly Met 195 200 205Ala Asp Arg Leu
Arg Ile Gln Gln Ala Gly Pro Lys Asp Val Val Leu 210
215 220Leu Ser Thr Ile Arg Arg Leu Lys Ser Ala Phe Phe
Asn Phe Ile Ile225 230 235
240Ser Ser Ala Val Ser Pro Glu Leu Pro Pro Glu Ala Val Leu Ser Leu
245 250 255Pro Cys Asp Cys Asp
Trp Ile Asp Ala Phe Leu Gln Arg Phe Ala Asp 260
265 270Pro Val Asp Leu Thr Met Leu Arg Thr Leu Arg Gly
Leu Ser Val Gln 275 280 285Thr Leu
Ile Lys Cys Ile Val Ser Ala Ile Ser Leu Pro Asn Thr Pro 290
295 300Arg Gln Ala Asn Leu Leu Gln Gly Ser Gly Leu
Arg Gly Gly Val Phe305 310 315
320Glu Leu Arg Pro Arg Glu Asp Gly Arg Ala Val Thr Glu Thr Met Arg
325 330 335Arg Arg Arg Gly
Glu Met Ile Glu Arg Phe Val Asp Arg Leu Pro Ile 340
345 350Arg Arg Arg Arg Arg Arg Val Pro Val Glu Val
Glu Ala Pro Val Met 355 360 365Glu
Ala Glu Glu Glu Glu Glu Val Pro Pro Arg Thr Phe Glu Glu Glu 370
375 380Val Arg Ala Thr Val Ala Asp Leu Ile Arg
Leu Leu Glu Glu Glu Leu385 390 395
400Thr Val Ser Ala Arg Asn Ser Gln Phe Phe Asn Phe Ala Ile Asp
Phe 405 410 415Tyr Glu Ala
Met Glu Arg Leu Glu Ala Val Gly Asp Ile Asn Glu Ser 420
425 430Thr Leu Arg Arg Trp Ile Met Tyr Phe Phe
Val Thr Glu His Ile Ala 435 440
445Thr Thr Leu Asn Tyr Leu Phe Gln Arg Leu Arg Asn Tyr Pro Val Phe 450
455 460Ser Arg His Val Glu Leu Asn Leu
Ala Gln Val Val Met Arg Ala Arg465 470
475 480Asp Asp Asp Gly Ala Val Val Tyr Ser Arg Val Trp
Asn Glu Asn Gly 485 490
495Leu Gly Ala Phe Ser Gln Leu Ile Gly Arg Ile Ser Asn Asp Leu Ala
500 505 510Ala Thr Val Glu Arg Ala
Gly Arg Gly Glu Leu Gln Glu Glu Glu Ile 515 520
525Asp Gln Leu Met Thr Glu Ile Ala Phe Gln Asp Asn Ser Gly
Asp Val 530 535 540His Glu Ile Leu Arg
Gln Ala Ala Ile Asn Asp Ala Asp Ile Asp Ser545 550
555 560Val Glu Leu Ser Phe Arg Phe Lys Val Thr
Gly Pro Val Val Phe Thr 565 570
575Gln Arg Gln Arg Ile Gln Asn Met Asn Arg Arg Val Val Ala His Ala
580 585 590Ser Arg Leu Arg Ser
Gln His Leu Pro Leu Pro Glu Ser His Ala Asp 595
600 605Val Asp Leu Pro Val Leu Pro Ala Gly Ala Glu Pro
Pro Leu Pro Pro 610 615 620Gly Ala Arg
Pro Arg Arg Arg His625 630421186PRTArtificial
SequenceSynthetic polypeptide 42Met Ala Leu Phe Gln Val Gln Ser Asn Arg
Thr Ser Gly Val Tyr Thr1 5 10
15Ala Ser Thr His Thr Glu His Glu Ser Pro Ser Gly Gly Ser Cys Gln
20 25 30Pro Ala Glu Val Pro Ala
Pro Thr Val Ala Arg Val Ser Arg Arg Arg 35 40
45Arg Ser Pro Ser Thr Ala Arg Arg Arg Arg Ala Ser Pro Ala
Pro Arg 50 55 60Arg Pro Thr Pro Ser
Pro Thr Leu Lys Lys Ser Leu Arg Gly Thr Val65 70
75 80Val Ala Ser Arg Ala His Gly Leu Ile His
Ala Ile Asp Thr Arg Asp 85 90
95His Ser Pro Val Glu Leu Lys Tyr His Leu His Leu Leu Pro Ala Leu
100 105 110Gln Arg Leu Phe Glu
Ile His Leu Leu Arg Phe Pro Ala Asp Leu Cys 115
120 125Thr Leu Pro Asp Thr Cys Gly Thr Asn Asp Val Gln
Arg Leu Val Ala 130 135 140Arg Leu Arg
Pro Ser Phe Ala Glu Ile Trp Thr Cys Ile Ser Arg Gly145
150 155 160Ala Val Lys Val Ala Val Leu
Pro Thr Asp Gly Gln Asn Gln Ser Thr 165
170 175Thr Asp Glu Ser Lys Gln Pro Gln Pro Asn Ser Pro
Ser Arg Val Pro 180 185 190Leu
Pro Phe Pro Leu Arg Phe Leu Ile Arg Gly Arg Lys Ala Tyr Leu 195
200 205Ile Gln Asp Val Thr Pro Met Gln Arg
Cys Glu Tyr Cys Ala Arg Phe 210 215
220Tyr Lys His Gln His Gln Cys Thr Ala Arg Arg Arg Asp Phe Tyr Phe225
230 235 240His His Val Ala
Val Gln Ser Ser Gln Trp Trp Arg Gln Ile Gln Phe 245
250 255Phe Pro Ile Gly Ser His Pro Ala Val Gln
Arg Leu Phe Val Thr Tyr 260 265
270Asp Val Glu Thr Tyr Thr Trp Met Gly Ser Phe Gly Lys Gln Leu Val
275 280 285Pro Phe Met Leu Val Met Lys
Phe Thr Gly Gln Ala Gln Leu Val Lys 290 295
300Thr Ala Val Asn Leu Ala Val Glu Leu Gln Trp Asn Arg Trp His
Ala305 310 315 320Asp Pro
Thr Thr Phe Tyr Leu Ile Thr Pro Glu Lys Met Val Ile Gly
325 330 335Lys Gln Phe Arg Cys Phe Arg
Asp Lys Leu Gln Ser Val Leu Cys Asp 340 345
350His Met Trp Asn Thr Phe Ala Asp Glu Asn Pro His Leu Thr
Phe Trp 355 360 365Cys Gln Gln Thr
Leu Gly Leu Cys Asp Pro Lys Glu Leu Thr Tyr Asp 370
375 380Gln Leu Val Ala Ala Pro Glu Leu Arg Gly Ser Pro
Gln Phe Leu Glu385 390 395
400Leu Tyr Ile Val Gly His Asn Ile Asn Gly Phe Asp Glu Ile Val Leu
405 410 415Ala Ala Gln Val Ile
Asp Asn Arg Thr Asp Val Pro Ala Pro Phe Lys 420
425 430Ile Ser Arg Asn Phe Ile Pro Arg Ala Gly Lys Ile
Leu Phe Asn Asp 435 440 445Val Thr
Leu Ser Leu Pro Asn Pro Lys Tyr Lys Gln Arg Lys Asp Phe 450
455 460Thr Leu Trp Glu Gln Gly Asn Cys Asp Asp Ser
Asp Phe Lys Asn Gln465 470 475
480Phe Leu Lys Val Met Val Arg Asp Thr Phe Gln Leu Thr His Thr Ser
485 490 495Leu Arg Lys Ala
Ala Gln Ala Tyr Ala Leu Pro Val Glu Lys Gly Cys 500
505 510Cys Pro Tyr Arg Ala Val Asn Glu Phe Tyr Met
Leu Gly Ser Tyr Gln 515 520 525Ala
Thr Ala Asp Gly Phe Pro Leu Arg Asn Tyr Trp Lys Asp Glu Ala 530
535 540Glu Tyr Leu Leu Asn Arg Glu Leu Trp Lys
Thr Lys Asn Lys Pro His545 550 555
560Tyr Asn Leu Ile Glu Glu Thr Leu Glu Tyr Cys Ala Leu Asp Val
Ile 565 570 575Val Thr Ala
Ala Leu Val Asp Lys Leu Phe Ser Ser Tyr Ala Gln Phe 580
585 590Ile Arg Glu Thr Val Gly Tyr Ser Asn Ser
Cys Phe Asn Val Phe Gln 595 600
605Arg Pro Thr Ile Ser Ser Asn Ser His Ala Ile Phe Arg Gln Ile Leu 610
615 620Tyr Thr Ala Gln Arg Pro Gln Lys
Thr Asn Leu Gly Pro Asn Phe Leu625 630
635 640Ala Pro Ser His Glu Leu Tyr Asp Tyr Val Arg Ser
Ser Ile Arg Gly 645 650
655Gly Arg Cys Tyr Pro Thr Tyr Leu Gly Val Leu Thr Glu Pro Leu Tyr
660 665 670Val Tyr Asp Ile Cys Gly
Met Tyr Ala Ser Ala Leu Thr His Pro Met 675 680
685Pro Trp Gly Pro Pro Leu Asn Pro Phe Glu Arg Ala Leu Ala
Ala Lys 690 695 700Asn Trp Gln Asp Ala
Leu Asn Ser Ser Ser Lys Ile Ser Tyr Phe Asp705 710
715 720Arg Leu Leu Leu Pro Gly Ile Phe Thr Ile
Asp Ala Asp Pro Pro Asp 725 730
735Glu Asn Leu Leu Asp Ile Leu Pro Pro Phe Cys Ser Arg Lys Gly Gly
740 745 750Arg Leu Cys Trp Thr
Asn Glu Arg Leu Arg Gly Glu Val Ala Thr Ser 755
760 765Ile Asp Met Val Thr Leu His Asn Arg Gly Trp Lys
Val Arg Leu Ile 770 775 780Pro Asp Glu
Arg Thr Thr Val Phe Pro Gln Trp Lys Cys Val Ala Arg785
790 795 800Glu Tyr Val Gln Leu Asn Ile
Ala Ala Lys Glu Lys Ala Asp Lys Asp 805
810 815Lys Asn Gln Thr Leu Arg Ser Ile Ala Lys Leu Leu
Ser Asn Ala Leu 820 825 830Tyr
Gly Ser Phe Ala Thr Lys Leu Asp Asn Lys Lys Thr Val Phe Ser 835
840 845Asp Gln Leu Asp Asp Lys Thr Leu Lys
Gly Ile Ala Ser Gly His Ile 850 855
860Asn Ile Lys Ser Ser Ser Phe Ile Glu Thr Asp Asn Leu Ser Ala Glu865
870 875 880Val Leu Pro Ser
Phe Gln Arg Val Tyr Ser Pro Lys Glu Leu Ala Leu 885
890 895Val Asp Ser Glu Pro Glu Glu Ser Asp Glu
Glu Arg Trp Asn Pro Pro 900 905
910Phe Tyr Ser Pro Pro Gln Asp Pro Gln Ser His Val Thr Tyr Thr Tyr
915 920 925Lys Pro Ile Ile Phe Leu Asp
Ala Glu Glu Thr Asp Leu Cys Leu His 930 935
940Thr Leu Glu Asn Thr Asp Pro Leu Ile Asp Asn Asp Arg Tyr Pro
Ser945 950 955 960Gln Ile
Ala Ser Phe Val Leu Ala Trp Thr Arg Ala Phe Val Ser Glu
965 970 975Trp Ser Glu Phe Leu Tyr Glu
Glu Asp Arg Gly Thr Pro Leu Ser Glu 980 985
990Arg Pro Leu Lys Ser Val Tyr Gly Asp Thr Asp Ser Leu Phe
Val Thr 995 1000 1005Asp Leu Gly
His Gln Leu Met Glu Thr Lys Gly Arg Lys Arg Ile 1010
1015 1020Lys Lys Asn Gly Gly Arg Leu Val Phe Asp Pro
Ser His Pro Glu 1025 1030 1035Leu Thr
Trp Leu Val Glu Cys Glu Thr Val Cys Glu Lys Cys Gly 1040
1045 1050Ala Asp Ala Tyr Ala Pro Glu Ser Val Phe
Leu Ala Pro Lys Leu 1055 1060 1065Tyr
Ala Leu Gln Cys Leu Tyr Cys Pro Arg Cys Gly His Val Ser 1070
1075 1080Lys Gly Lys Leu Arg Ala Lys Gly His
Ala Ala Glu Ser Leu Ser 1085 1090
1095Tyr Asp Leu Leu Val Lys Cys Tyr Leu Ala Asp Tyr Gln Gly Gly
1100 1105 1110Asn Glu Gln Phe Ser Thr
Ser Arg Met Ser Leu Lys Arg Thr Leu 1115 1120
1125Ala Ser Ala Gln Pro Gly Ala His Pro Phe Thr Val Thr Glu
Thr 1130 1135 1140Thr Leu Thr Arg Thr
Leu Arg Pro Trp Lys Asp Met Thr Leu Thr 1145 1150
1155Pro Leu Asp Ala His Arg Leu Val Pro Tyr Ser Asn Ser
Gln Pro 1160 1165 1170Asn Pro Arg Asn
Gln Glu Ile Tyr Trp Ile Glu Met Pro 1175 1180
118543582PRTArtificial SequenceSynthetic polypeptide 43Met Gln
Arg Pro Ala Ala Met Ala Ser Thr Glu Thr Glu Pro Met Asp1 5
10 15Pro Val Val Arg Ala Ala Leu Gln
Ser Gln Pro Ser Gly Val Ala Pro 20 25
30Ser Asp Asp Trp Ser Ala Ala Met Asp Arg Ile Met Ala Leu Thr
Ala 35 40 45Arg Asn Ser Glu Ala
Phe Arg Gln Gln Pro Gln Ala Asn Arg Phe Ser 50 55
60Ala Ile Leu Glu Ala Val Val Pro Ser Arg Pro Asn Pro Thr
His Glu65 70 75 80Lys
Val Leu Ala Ile Val Asn Ala Leu Ala Glu Asn Arg Ala Ile Arg
85 90 95Pro Asp Glu Ala Gly Gln Ile
Tyr Asn Ala Leu Leu Glu Arg Val Ala 100 105
110Arg Tyr Asn Ser Thr Asn Val Gln Ser Asn Leu Asp Arg Leu
Val Thr 115 120 125Asp Val Arg Glu
Ala Val Ala Gln Arg Glu Arg Phe His Lys Asp Ala 130
135 140Asn Leu Gly Ser Met Val Ala Leu Asn Ala Phe Leu
Ser Ser Leu Pro145 150 155
160Ala Asn Val Pro Arg Gly Gln Glu Asp Tyr Thr Asn Phe Ile Ser Ala
165 170 175Leu Arg Leu Met Val
Ala Glu Val Pro Gln Ser Glu Val Tyr Met Ser 180
185 190Gly Pro Ser Tyr Tyr Phe Gln Thr Ser Arg Gln Gly
Leu Gln Thr Val 195 200 205Asn Leu
Ser Gln Ala Phe Lys Asn Leu Glu Gly Leu Trp Gly Val Lys 210
215 220Ala Pro Leu Gly Asp Arg Ala Thr Val Ser Ser
Leu Leu Thr Pro Asn225 230 235
240Thr Arg Leu Leu Leu Leu Leu Ile Ala Pro Phe Thr Asp Ser Gly Ser
245 250 255Ile Ser Arg Asp
Ser Tyr Leu Gly His Leu Ile Thr Leu Tyr Arg Glu 260
265 270Ala Ile Gly Gln Ser Arg Val Asp Glu His Thr
Tyr Gln Glu Ile Thr 275 280 285Asp
Val Ser Arg Ala Met Gly Gln Glu Asp Thr Ser Ser Leu Gln Ala 290
295 300Thr Leu Asn Tyr Leu Leu Thr Asn Arg Arg
Gln Arg Ile Pro Pro Gln305 310 315
320Phe Ser Leu Ser Pro Glu Glu Glu Arg Ile Leu Arg Tyr Val Gln
Gln 325 330 335Ser Val Ser
Leu Tyr Leu Met Arg Glu Gly Asp Gly Pro Ser Ala Ala 340
345 350Leu Asp Leu Thr Ala Arg Asn Met Glu Pro
Gly Leu Tyr Ser Thr Asn 355 360
365Arg Ala Phe Ile Asn Arg Leu Met Asp Tyr Leu His Arg Ala Ala Ala 370
375 380Leu Asn Pro Glu Tyr Phe Asn Asn
Ala Val Leu Asn Pro His Trp Leu385 390
395 400Pro Pro Pro Gly Phe Tyr Thr Gly Glu Phe Asp Leu
Pro Glu Ala Asn 405 410
415Asp Gly Phe Ile Trp Asp Asp Asp Thr Ser Val Phe Ser Pro Met Gln
420 425 430Lys Lys Glu Gly Gly Asp
Ala Gln Ser Gln Arg Val Ser Leu Ala Ser 435 440
445Met Gly Ala Ser Val Ala Ser Pro Leu Pro Ser Phe Ser Ser
Ala Ser 450 455 460Ser Ala Ala Gly Arg
Val Asn Arg Pro Arg Leu Ser Gly Glu Thr Asp465 470
475 480Tyr Leu Asn Asp Pro Leu Met Arg Pro Ala
Arg Ala Lys Asn Phe Pro 485 490
495Asn Asn Gly Ile Glu Ser Leu Val Asp Lys Met Ser Arg Trp Lys Thr
500 505 510Tyr Ala Gln Glu Gln
Arg Glu Trp Glu Glu Gln Gln Pro Arg Pro Leu 515
520 525Ile Pro Pro Thr Arg Gly Asn Arg Arg Arg Arg Gln
Asp Met Gly Pro 530 535 540Tyr Arg Val
Pro Val Asp Pro Glu Asp Ser Ala Asp Asp Ser Ser Val545
550 555 560Leu Asp Leu Gly Gly Ser Gly
Asn Pro Phe Ala His Leu Arg Pro Gln 565
570 575Gly Arg Ile Gly Lys Trp
58044375PRTArtificial SequenceSynthetic polypeptide 44Met His Pro Val Leu
Arg Gln Met Arg Pro Ser Asn Ser Gly Pro Ala1 5
10 15Thr Thr Ala Ala Gly Ala Val Cys Gln Ala Gly
Ala Gly Asn Pro Leu 20 25
30Glu Glu Val Leu Asp Ile Glu Glu Gly Glu Gly Leu Ala Arg Leu Gly
35 40 45Ala His Ser Pro Glu Arg His Pro
Arg Val Gln Leu Lys Lys Asp Ser 50 55
60Ser Glu Ala Tyr Ile Pro Pro Arg Asn Leu Phe Arg Glu Arg Ser Gly65
70 75 80Glu Glu Ala Glu Glu
Met Arg Asp Ser Arg Phe Arg Ala Gly Arg Glu 85
90 95Leu Lys Lys Gly Leu Asp Arg Glu Arg Leu Leu
Arg Pro Glu Asp Phe 100 105
110Glu Ala Arg Asp Arg Thr Gly Val Ser Ala Ala Arg Ala His Val Ala
115 120 125Ala Ala Asp Leu Val Thr Ala
Tyr Glu Gln Thr Val Lys Glu Glu Met 130 135
140Asn Phe Gln Lys Ser Phe Asn Asn His Val Arg Thr Leu Ile Ala
Arg145 150 155 160Glu Glu
Val Ala Ile Gly Leu Met His Leu Trp Asp Phe Leu Glu Ala
165 170 175Tyr Val Gln Asn Pro Thr Ser
Lys Pro Leu Thr Ala Gln Leu Phe Leu 180 185
190Ile Val Gln His Ser Arg Asp Asn Glu Thr Phe Arg Asp Ala
Leu Leu 195 200 205Asn Ile Ala Glu
Pro Glu Gly Arg Trp Leu Leu Asp Leu Ile Asn Ile 210
215 220Leu Gln Ser Ile Val Val Gln Glu Arg Ser Leu Ser
Leu Ala Asp Lys225 230 235
240Val Ala Ala Ile Asn Tyr Ser Met Leu Ser Leu Gly Lys Phe Tyr Ala
245 250 255Arg Lys Ile Tyr Lys
Thr Pro Tyr Val Pro Ile Asp Lys Glu Val Lys 260
265 270Ile Asp Ser Phe Tyr Met Arg Met Ala Leu Lys Val
Leu Thr Leu Ser 275 280 285Asp Asp
Leu Gly Ile Tyr Arg Asn Asp Arg Ile His Lys Ala Val Ser 290
295 300Ala Ser Arg Arg Arg Glu Leu Ser Asp Arg Glu
Leu Met Tyr Ser Leu305 310 315
320Gln Arg Ala Leu Thr Gly Thr Gly His Gly Gln Asp Glu Asn Leu Phe
325 330 335Asp Ala Gly Ala
Asp Leu Lys Trp Gln Pro Ser Arg Arg Ala Trp Gln 340
345 350Ala Ala Gly Thr Tyr Leu Glu Ser Ile Glu Glu
Asp Glu Asp Glu Asp 355 360 365Pro
Glu Asn Glu Pro Ile Asp 370 37545475PRTArtificial
SequenceSynthetic polypeptide 45Arg Thr Arg Leu Gln Arg Lys Thr Ser Ser
Gln Gly Ser Arg Gly Arg1 5 10
15Val Pro Gln Leu Arg Pro Phe Ser Glu Met Leu Pro Cys Arg Leu Pro
20 25 30Gly Arg Lys Arg Thr Val
Leu His Glu Ser Asp Glu Phe Glu Ala His 35 40
45Pro Ser Lys Arg Pro Thr Arg Ser Thr Pro Phe His Arg Asn
Gly Asp 50 55 60His Thr His Glu Asn
Pro Pro Pro Leu Glu Gly His Asp Ala Asp Thr65 70
75 80Ser Gly Arg Pro Pro Ala Gly Ser Leu Gln
Gln Gln Pro Thr Gln Pro 85 90
95Lys Lys Pro Gly Asn Leu Leu Asp Arg Asp Ala Val Glu His Val Thr
100 105 110Glu Leu Trp Asp Arg
Leu Gln Leu Leu Cys Gln Ser Leu Gln Asn Met 115
120 125Pro Leu Ala Glu Gly Leu Lys Pro Leu Lys Lys Phe
Ala Ser Leu Gln 130 135 140Glu Leu Leu
Ser Leu Gly Gly Pro Arg Leu Leu Arg Glu Leu Val Gln145
150 155 160Glu Asn Leu His Val Gln Asp
Met Met Asn Glu Val Ala Pro Leu Leu 165
170 175Ala Asp Asp Gly Ser Cys Thr Ser Leu Asn Tyr His
Leu Gln Pro Val 180 185 190Ile
Ala Val Ile Tyr Gly Pro Thr Gly Ser Gly Lys Ser Gln Leu Leu 195
200 205Arg Asn Leu Leu Ser Thr Gln Leu Ile
Ser Pro Ala Pro Glu Thr Val 210 215
220Phe Phe Ile Ala Pro Gln Val Asp Met Ile Pro Pro Ala Glu Ile Lys225
230 235 240Ala Trp Glu Met
Gln Ile Cys Glu Gly Asn Phe Arg Ala Gly Pro Glu 245
250 255Gly Thr Leu Val Pro Gln Ser Gly Thr Leu
Lys Pro Arg Phe His Lys 260 265
270Met Ser Tyr Asp Glu Leu Thr Gln Asp Tyr Asn Tyr Asp Val Thr Asp
275 280 285Pro Arg Asn Val Phe Ala Arg
Ala Ala Val Gln Gly Pro Ile Ala Ile 290 295
300Ile Met Asp Glu Cys Met Glu Asn Leu Gly Gly His Lys Gly Ile
Ser305 310 315 320Lys Phe
Phe His Ala Phe Pro Ser Lys Leu His Asp Lys Phe Pro Lys
325 330 335Cys Thr Gly Tyr Thr Val Leu
Val Val Leu His Asn Met Asn Pro Arg 340 345
350Arg Asp Leu Gly Gly Asn Ile Ser Asn Leu Lys Ile Gln Ser
Lys Leu 355 360 365His Ile Met Ser
Pro Arg Met His Pro Ser Gln Leu Asn Arg Phe Ile 370
375 380Asn Thr Tyr Thr Lys Gly Leu Pro Val Ala Ile Thr
Leu Leu Leu Lys385 390 395
400Asp Ile Phe Gln His His Ala Gln Arg Asn Ser Tyr Asp Trp Ile Ile
405 410 415Tyr Asn Thr Thr Pro
Glu His Glu Ala Leu Gln Trp Ser Tyr Leu His 420
425 430Pro Lys Asp Gly Leu Met Pro Met Tyr Leu Asn Ile
Gln Thr His Leu 435 440 445Tyr Arg
Val Met Glu Lys Ile His Lys Val Leu Asn Asp Arg Glu Arg 450
455 460Trp Ser Arg Ala Tyr His Lys Lys Asn Arg
Gln465 470 47546134PRTArtificial
SequenceSynthetic polypeptide 46Met Ser Gly Thr Thr Ser Gly Ser Val Thr
Phe Asp Gly Gly Val Tyr1 5 10
15Ser Pro Phe Leu Thr Ser Arg Leu Pro Asn Trp Ala Gly Val Arg Gln
20 25 30Asn Val Met Gly Ser Thr
Val Glu Gly His Pro Val Leu Pro Ser Asn 35 40
45Ser Ala Ser Met Arg Tyr Ala Thr Ile Gly Ser Ser Ser Leu
Asp Thr 50 55 60Ala Ala Ala Ala Ala
Ala Ser Ala Ala Ala Ser Ala Thr Arg Val Leu65 70
75 80Ala Ala Asp Phe Gly Leu Tyr Gly Asn Phe
Thr Pro Ala Ala Val Pro 85 90
95Arg Thr Val His Asp Asp Ser Leu Leu Thr Val Leu Thr Lys Leu Asp
100 105 110Asn Leu Thr Gln Gln
Leu Gly Glu Leu Ser Arg Arg Val Ala Glu Leu 115
120 125Ala Glu Glu Arg Thr Val 13047496PRTArtificial
SequenceSynthetic polypeptide 47Met Glu Gly Leu His Glu Glu Gly Glu Asp
Leu His Leu Leu Ala Gly1 5 10
15Ala Ala Val Ala Ala Ala Ala Gly Ala Glu Ala Val Gly Val Gln Asp
20 25 30Arg Gly Pro Asn Ala Leu
Ala Gly Gly Arg Gly Gly Ala Gln Gly Gly 35 40
45Asp Gly Ser Pro Glu Arg Asp Leu Ser Asp Asp Gln Glu Val
Pro Ala 50 55 60Ala Val Gly Pro Ile
Pro Asp Pro Phe Pro Glu Leu Arg Arg His Leu65 70
75 80Leu Arg Ser Pro Gly Arg Gly Leu Glu Glu
Asp Pro Gly Glu Gly Gly 85 90
95Ser Gly Glu Gln Arg Gly Ile Lys Arg Pro Arg Glu Gly Arg Lys Val
100 105 110Glu Gly Ile Met Ser
Glu Leu Thr Leu Ser Leu Met Thr Arg Lys Arg 115
120 125Thr Glu Asn Lys Trp Leu Ser Glu Ile Trp Asp Glu
Phe Arg Thr Gly 130 135 140Asp Met Tyr
Leu Gln Thr Lys Tyr Thr Phe Glu Gln Val Phe Thr Lys145
150 155 160Trp Leu Asn Pro Glu Asp Asp
Trp Glu Asp Ala Leu Thr Arg Tyr Gly 165
170 175Lys Val Ala Leu Arg Pro Asp Thr Lys Tyr Arg Leu
Thr Lys Lys Val 180 185 190Glu
Leu Arg Ser Cys Ala Tyr Val Ile Gly Asn Gly Ala Gln Val Glu 195
200 205Val Asp Met Gln Glu Arg Val Ala Phe
Ala Cys Asn Met Val Asn Met 210 215
220Gly Pro Gly Ile Val Gly Met Gly Gly Ile Ile Phe His Asn Val Arg225
230 235 240Phe Tyr Gly Asp
Asn Phe Asn Gly Met Val Ile Met Ala Asn Thr Thr 245
250 255Val Leu Leu His Gly Cys Tyr Phe Phe Gly
Phe Asn Asn Thr Val Leu 260 265
270Glu Val Trp Gly His Ser Lys Val Arg Gly Cys Thr Phe Tyr Gly Cys
275 280 285Trp Lys Ala Ile Ala Ser Arg
Pro Lys Ser Glu Ile Ser Val Lys Lys 290 295
300Cys Leu Phe Glu Arg Cys Thr Leu Gly Val Cys Val Glu Gly Lys
Gly305 310 315 320Arg Ile
Phe Asn Asn Val Ala Ser Glu Asn Gly Cys Phe Ala Leu Ile
325 330 335Lys Gly Phe Ala Ala Leu Lys
Tyr Asn Met Ile Cys Gly Gln Ser Pro 340 345
350Thr Glu Arg Thr Tyr Gln Met Leu Thr Cys Ala Asp Gly Asn
Val His 355 360 365Leu Leu Lys Thr
Val His Ile Thr Gly His Ala Lys Lys Pro Trp Pro 370
375 380Leu Phe Glu His Asn Val Leu Thr Arg Cys Ser Val
His Leu Gly Pro385 390 395
400Arg Arg Gly Ile Phe Ile Pro His Gln Cys Asn Phe Ser His Thr Asn
405 410 415Val Leu Val Glu Thr
Glu Ala Val Thr Arg Phe Ser Leu Thr Gly Val 420
425 430Phe Asp Met Ser Val Val Ile Tyr Lys Ile Leu Arg
Tyr Glu Glu Thr 435 440 445Lys Ala
Arg Cys Arg Cys Cys Glu Cys Gly Gly Lys His Leu Arg Asn 450
455 460Gln Pro Val Ile Val Asp Val Thr Glu Glu Val
Arg Met Asp His Met465 470 475
480Gln His Ser Cys Ala Arg Ala Asp Tyr Ser Thr Asp Glu Asp Thr Glu
485 490
49548177PRTArtificial SequenceSynthetic polypeptide 48Met Glu Leu Asp Arg
Leu Leu Glu Asn Tyr Asn Ser Leu Arg Arg Val1 5
10 15Leu Glu Glu Ala Ser Glu Asp Thr Ser Val Trp
Trp Arg Lys Leu Phe 20 25
30Gly Cys Arg Val Ser Gln Leu Val Val Gln Ala Lys Val Glu Tyr Lys
35 40 45Glu Glu Phe Glu Lys Leu Phe Ser
Glu Val Pro Gly Leu Val Asp Ser 50 55
60Leu Asn Phe Cys His His Ala Phe Phe Tyr Glu Lys Val Ile Cys Gly65
70 75 80Leu Asp Phe Cys Thr
Pro Gly Arg Thr Ile Ala Ala Leu Ala Phe Cys 85
90 95Ala Phe Ile Leu Asp Lys Trp Asn Lys Glu Thr
His Leu Ser Lys Gly 100 105
110Tyr Thr Leu Asp Tyr Ile Ser Leu Gln Leu Trp Lys Ala Tyr Met Arg
115 120 125Lys Gly Lys Ile Tyr Thr Phe
Ser Gln Gly Pro Arg Ser Leu Pro Gln 130 135
140Arg Val Arg Arg Arg Leu Gly Phe Lys Thr Glu Asp Gln Thr Arg
Leu145 150 155 160Leu Glu
Ala Glu Glu Glu Pro Arg Ala Gly Thr Asp Pro Pro Ser Glu
165 170 175Thr49272PRTArtificial
SequenceSynthetic polypeptide 49Met Arg Thr Pro Leu Val Glu Gly Asp Ile
Pro Val Arg Phe Ala Ala1 5 10
15Glu Leu Leu Ala Ala Leu Ala Glu Glu Val Phe Ala Asp Val Glu Pro
20 25 30Pro Arg Ala Phe Glu Asp
Val Ser Leu His Asp Leu Phe Asp Leu Asp 35 40
45Val Glu Asp Arg Glu Asp Pro Ser Gln Asp Ala Val Asp Met
Leu Phe 50 55 60Pro Glu Ser Leu Leu
Leu Ala Ala Glu Glu Gly Ile Asp Ile Pro Arg65 70
75 80Asp Thr Pro Pro Pro Leu Glu Pro Pro Met
Val Leu Ser Pro Leu Ser 85 90
95Gln Gln Gln Gln Asp Met Pro Asp Leu Thr Val Gly Asp Val Asn Leu
100 105 110Leu Cys Ser Glu Ser
Ser Phe Ser Ser Leu Glu Glu Asn Glu Leu Glu 115
120 125Arg Cys Met Ala Glu Leu Ala Ala Ser Gly Val Ala
Ser Val Arg Glu 130 135 140Gln Glu Arg
Glu Glu Met Ser Gly Thr Pro Phe Asn Leu Asp Tyr Pro145
150 155 160Glu Met Pro Gly Tyr Gly Cys
Lys Ser Cys Gln Tyr His Arg Glu Gln 165
170 175Thr Gly Glu Ala Asp Ile Leu Cys Ser Leu Cys Tyr
Leu Arg Arg Asn 180 185 190Gly
Val Phe Val Tyr Ser Pro Val Ser Glu Ala Glu Val Asp Glu Pro 195
200 205Asp Thr Thr Thr Asp Asp Gln Gly Arg
Ala Gln Ser Pro Pro Lys Leu 210 215
220Thr Gln Asp Ala Pro Val Asn Val Ile Arg Pro Arg Pro Ile Arg Pro225
230 235 240Ser Ser Arg Arg
Arg Asn Ala Val Asp Ser Leu Glu Ser Leu Leu Glu 245
250 255Asp Asp Asp Cys Glu Pro Leu Asp Leu Thr
Phe Lys Arg Ala Arg Tyr 260 265
27050128PRTArtificial SequenceSynthetic polypeptide 50Met Ala Thr Asn
Glu Glu Phe Leu Tyr Val Tyr Arg Glu Gly Glu His1 5
10 15Gly Ile Leu Pro Val Gln Glu Gly Tyr Ser
Gly Val Tyr Thr Leu Phe 20 25
30Ser Pro Glu Asp Phe Val Ile Pro Pro Glu Gly Val Leu Leu Leu Tyr
35 40 45Leu Gln Ile Arg Val Gln Val Pro
Pro Gly Tyr Ile Gly Arg Leu Gly 50 55
60Pro Leu Gly Asp Leu Val Arg Arg Gly Ile Phe Ala Gly Ala Asp Thr65
70 75 80Val Asp Pro Cys Thr
Arg Trp Glu Leu Lys Leu Leu Leu Phe Asn His 85
90 95Thr Pro Asp Phe Tyr His Gly Gln Arg Gly Gln
Ala Val Gly Arg Phe 100 105
110Leu Leu His Arg Val Ile Tyr Pro Thr Val Leu Glu Ala Thr Gln Val
115 120 125
User Contributions:
Comment about this patent or add new information about this topic:
People who visited this patent also read: | |
Patent application number | Title |
---|---|
20110199838 | SEMICONDUCTOR STORAGE DEVICE |
20110199837 | High Voltage Word Line Driver |
20110199836 | BIT-LINE SENSE AMPLIFIER, SEMICONDUCTOR MEMORY DEVICE HAVING THE SAME, AND METHOD OF TESTING BIT-LINE MICRO-BRIDGE DEFECT |
20110199835 | No-Disturb Bit Line Write for Improving Speed of eDRAM |
20110199834 | METHOD FOR DRIVING A NONVOLATILE SEMICONDUCTOR MEMORY DEVICE |